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1 Abstract 
Medicinal products are a special good. Under the right circumstances, they can 
help by preventing, alleviating and curing diseases and even save lives. On the 
other hand, medicinal products under the wrong circumstances can have serious 
consequences by remaining either ineffective or causing adverse effects that may 
range from mild discomfort to fatal reactions. In order to protect society from 
possible harms special regulations are required for a secure handling of medicinal 
products. In addition to country specific medicines regulations the EU has 
developed its own legal framework for medicinal products over the years to 
harmonize the requirements across the European countries. The requirements for 
market authorisation for products for human use are set in Directive 2001/83/EC. 
Besides this Directive, several other regulations exist on European or Member 
State level that ensure high standards and safety in the development, testing, 
manufacturing, trade, advertising and use of medicinal products. The entirety of 
the regulations concerning medicines are intended to protect society, to identify 
the right circumstances under which medications are beneficial and to ensure an 
overall high quality of the products. 
The scope of this thesis is to explain potential limits of the current system and 
suggest a possible new approach to overcome certain limits by expanding the 
current legislation. It gives an overview on the current regulatory system, 
particularly the requirements for market authorisation of medicinal products for 
human use.  
A particular limit of the existing regulation that was identified in this thesis is the 
remote possibility of the approval of combination therapies, meaning therapy in 
which more than one medication is used. Usually, active agents are evaluated in 
terms of their individual safety and efficacy. For exceptional cases, guidelines and 
regulations exist for the approval of specific combinations, such as fixed 
combinations, which includes two or more active agents within a single 
pharmaceutical form. The free combination of individual medications or other 
medical products is however currently not reflected in the legal framework. Yet 
combinations of different medicinal products are widely use in the medical 
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practice and are in fact essential for the treatment of several diseases but this is not 
taken into account in the approval process. Thus, a gap between treatment reality 
and regulatory approval exists. A possible approach for closing this gap is 
presented in this thesis: the introduction of “therapeutic concepts”. Therapeutic 
concepts describe the marketing authorisation of a treatment regime consisting of 
a combination of two or more individual medicinal products for a defined 
condition or a combination of a medicinal product and a companion device that is 
compulsory for diagnosis or decision-making whether the medicinal product in 
question is appropriate for treatment that have been developed and studied 
together. Products included in the therapeutic concept may or may not have been 
marketed prior to the approval in the therapeutic concept. Therapeutic concepts 
can be regarded as an integrative approach based on the current framework. The 
approach would be an addition to the present legislation to meet existing needs. 
Compared to fixed combinations the free combinations of a therapeutic concept 
would offer additional benefits, such as better dosage adjustment based on the 
individual patient’s need.  
At present, combinations of medicinal products in certain conditions are for 
example described in medical guidelines. However, medical guidelines differ 
greatly in quality from each other, having the status of recommendation and 
cannot be equated with a market authorisation. Defined regulations for a market 
authorisation of combinations based on evidence obtained from clinical studies 
provide a greater knowledge and control on combinations in use and an improved 
legal certainty compared to medical guidelines.  
Combinations of different medicinal products have been commonly used as 
treatment systems, often in complex or multifactorial diseases, such as bacterial 
infection (e.g. tuberculosis), cardiovascular diseases or cancer. Current research 
focuses now on genetics-associated diseases, which also often require a complex 
combination of diagnostics and medicine. This field of research is referred to as 
personalized medicine as the patient’s individual disease and metabolic markers 
are analysed to stratify patients into subgroups which receive a therapy based on 
their genetic profile that is more likely to be effective compared to an alternative 
medication. Due to the complexity of the treatment approach and the involvement 
of both medicinal products and diagnostics, which are mainly medical devices, the 
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field of personalized medicine would profit from approved therapeutic concepts 
and would be a possible area for the application of therapeutic concepts.  
The link between medicinal products and medical devices, which are actually 
subject to different regulations, can be strengthened by therapeutic concepts. The 
connection between medicinal products and a diagnostic whose result determines 
whether the medicinal product is effective is of particular importance as both 
products contribute to the overall treatment outcome and should therefore be 
considered as a unit.  
For a possible implementation of therapeutic concepts as a new regulatory 
approval pathway, several aspects have to be considered. The design of pivotal 
studies for the approval process should allow as much evidence on safety and 
effectiveness as possible without too many control arms in the study as this might 
be too time and cost-consuming and requires a high number of participants. 
Labelling, reimbursement and risk management are particularly challenging for 
therapeutic concepts. Labelling must be designed in such a way that the individual 
medicinal product can be identified as part of an approved therapeutic concept. 
Risk management und vigilance plans should be more extensive to reflect to 
additional risk caused by the combination.  
Therapeutic concepts as a new regulatory pathway offer a regulatory change from 
which all stakeholders would profit and which has various possible fields of 
application. 
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2 Methods and Material 
The research methodology applied for this thesis is a combination of literature 
research and comparison of the legislation that includes laws, guidelines, 
regulations and standards.  
Researched literature is retrieved from publicly available online databases for 
medical literature. PubMed is a metadatabase developed by the National Center 
for Biotechnology Information (NCBI, USA) and is one of the largest and most 
widely used databases for biomedical literature. PubMed gives free access to the 
database Medline, a U.S. National Library of Medicine (NLM) bibliographic 
database covering literature on medicine, pharmacy, dentistry, veterinary 
medicine, psychology, public health, biology, biochemistry, molecular and 
genetic information. Medline comprises more than 22 million life science journal 
articles from more than 5,600 journals worldwide to date.1  
Google Scholar is a search engine for scholarly literature in general and thus gives 
a broader range for search.2 It was found to index similar literature as Medline but 
adds additionally own citations from other sources such as presentations, books 
and journals not covered by Medline or PubMed. Search strategies were adapted 
according to the line of research. Starting point was research on “combination 
therapy” to identify commonly used combinations and approaches how and why 
specific combinations are used. The search revealed the complex and 
heterogeneous nature of this subject that led to the focus on “personalized 
medicine” and “co-development” for further investigation.  
Parallel to scientific literature the legal basis for the corresponding subjects was 
examined. The consideration of the legal framework provided information on the 
current and/or prospective regulations applicable for pharmaceuticals and medical 
devices. Information were gathered concerning regulations mainly in Europe and 
Germany as well as the USA to provide different aspects and approaches on 
handling pharmaceutical and health related issues. EudraLex is the collection of 
rules governing the medicinal products in the European Union and serves as main 
                                                 
1
 NIH. Fact Sheet Medline. 23 Jun 2016 [Accessed on: 26 Jun 2016]. 
https://www.nlm.nih.gov/pubs/factsheets/medline.html.  
2
 Google. About Google Scholar. [Accessed on: 26 Jun 2016]. 
https://scholar.google.de/intl/de/scholar/about.html. 
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source for research. The ten volumes of EudraLex are also available online and 
deal with pharmaceuticals for human and veterinary use, marketing authorisation, 
clinical trials, manufacturing, and vigilance.3 Information on country specific 
legislation can usually be retrieved by accessing material available from 
competent authorities.  
Decisions of German courts for relevant issues were obtained from 
www.dejure.org, an internet based platform that comprises more than 1,000,000 
court decisions with references to the corresponding laws.4  
Comparison of rules and regulations over time allows conclusions on the overall 
developments in the area of medicinal products and reflects the progress of the 
scientific evolvement. In conjunction with the focus of the scientific literature and 
position papers by interested parties, the current needs and demands of the various 
stakeholders, which are drivers for change in the regulatory landscape, can be 
recognized. Based on the results of the literature and regulation research the 
proposed approach presented in this thesis was developed.  
  
                                                 
3
 European Commission. EU legislation – Eudralex. [Accessed on: 26 Jun 2016]. 
http://ec.europa.eu/legislation/index_en.htm.  
4
 Dejure. Was ist dejure.org eigentlich? [Accessed on: 26 Jun 2016]. https://dejure.org/verzahnung.  
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3 Regulations and authorisation of medicinal products 
3.1 National and international regulations  
Various national and international regulations and laws regulate the principles for 
manufacturing, approval and marketing of human medicinal products. The 
European Union has harmonized the pharmaceutical legislation by several 
regulations in the past years. The most important European regulation regarding 
human medicinal products is Directive 2001/83/EC relating to medicinal products 
for human use. The directive has been implemented in the national legislation of 
each member state. In Germany, the corresponding law is the German Drug Law 
(Arzneimittelgesetz (AMG)) from 1976 and amendments.  
3.2 Approval and authorities 
Before a finished medicinal product may be placed on the market in the European 
Union, a governmental authority to evaluate whether the drug is safe, effective 
and meets the necessary pharmaceutical quality must first examine it. 
Article six of Directive 2001/83/EC of the European Parliament and the Council 
states  
No medicinal product may be placed on the market of a Member State 
unless a marketing authorisation has been issued by the competent 
authorities of that Member State in accordance with this Directive […]. 
Hence, prior to marketing a medicinal product in the European Union, the 
pharmaceutical entrepreneur of the product must apply for a marketing 
authorisation issued by a competent authority. According to §4 AMG, the 
pharmaceutical entrepreneur is the holder of the approval or registration of the 
medicinal product. The pharmaceutical entrepreneur is also any person who places 
medicinal products on the market under their own name. A competent authority 
must issue the approval of the medicinal product. In Germany, the competent 
authority for the approval of human medicinal products is the BfArM, which is an 
independent federal higher authority within the portfolio of the Federal Ministry 
of Health (Bundesministerium für Gesundheit). The Paul-Ehrlich-Institut (PEI) is 
responsible for serums, vaccines, allergens test, test sera, test antigens, and blood 
preparations. The Federal Office of Consumer Protection and Food Safety 
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(Bundesamt für Verbraucherschutz und Lebensmittelsicherheit) approve 
veterinary drugs (BVL). The European Commission grants a marketing 
authorisation for the entire EEA after assessment procedure and positive 
recommendation by the European Medicines Agency (EMA) in London. 
3.2.1 Criteria for approval 
The medicinal product to be approved must necessarily meet three criteria 
 Efficacy 
 Safety  
 Quality 
Only those products that meet these three essential criteria are granted market 
access.5  
The efficacy of the product should be demonstrated by pre-clinical and clinical 
data. It must be proven that the product is effective under the defined 
specification. Therefore, the product should be tested in clinical studies in its 
intended use in a selected population with an appropriate dose regimen. Efficacy 
means the ability of the product to treat the condition it is intended for in the label.  
The assessment of a drug’s safety is based on its relative benefit-risk ratio. This 
implies that for a product with a high benefit, for example for serious, life-
threatening diseases or in diseases with little or no treatment alternatives, a higher 
risk may be tolerated than in drugs for a simple headache. Unacceptable serious 
adverse reactions are usually not tolerated. These reactions may be carcinogenic, 
genotoxic or teratogen effects; however, an unacceptable adverse reaction is 
always relative. Predicable adverse effects should be managed by determination of 
exclusion criteria and contraindications or other suitable measures.  
Important criteria for the pharmaceutical quality of a drug are purity, stability and 
bioavailability. These parameters can be influence by the manufacturing process.  
                                                 
5
 BfArM. Arzneimittelzulassung. [Accessed on: 26 Jun 2016]. 
http://www.bfarm.de/DE/Arzneimittel/zul/_node.html 
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3.2.2 Common Technical Document (CTD) 
To harmonize the format in which the pharmaceutical entrepreneur submits the 
required data the ICH introduced the Common Technical Document (CTD) 
format. All information regarding the drug approval is presented to the authority 
in order to facilitate the regulatory review process in a mandatory format. The 
CTD consist of five modules. Module 1 contains the regional administrative 
information and is not considered part of the CTD. Module 2 encloses the table of 
content, an introduction and also the overall quality summary, non-clinical as well 
as clinical overview and summaries. Module 3 focusses in the pharmaceutical and 
biological data of the active agent and on manufacturing processes and other 
quality relevant matters. Non-clinical study reports are part of Module 4, the 
clinical trials and the analysis of clinical data are covered in Module 5.6 Figure 1 
provides an overview on the CTD format. Article 8 section 3 of Directive 
2001/83/EC (and §§22 - 24 AMG for Germany) specifies the data that are 
required for the application.  
  
                                                 
6
 ICH. M4 : The Common Technical Document. [Accessed on: 26 Jun 2016]. 
http://www.ich.org/products/ctd.html  
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Figure 1 CTD Triangle: The Common Technical Document, developed as part of the 
harmonization of the drug authorisation procedures in the European Union, the US and Japan by 
the ICH, is organized into five modules. Module 1 is region specific and modules 2, 3, 4 and 5 are 
intended to be common for all regions.7  
  
                                                 
7
 ICH. CTD Triangle. [Accessed on: 26 Jun 2016]. 
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/CTD/CTD_triangle.pdf.  
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3.3 Approval procedures 
Different routes to obtain a marketing authorisation exist within the European 
Union. The requirements for approval of medicinal products were largely 
harmonized within the EU to allow simpler market access throughout the Union. 
In addition to national marketing authorisations, decentralised and centralised 
approaches for EU-wide approval were introduced. The national procedure allows 
market access for one specific Member State. Currently, there are two procedures, 
by which marketing authorisation for several Member States can be obtained: 
Mutual Recognition Procedure and Decentralised Procedure. A marketing 
authorisation that has been approved via the centralised procedure is valid for the 
entire EEA. The following sections give an overview on the different procedures.  
3.3.1 National Procedure 
To obtain a marketing authorisation for a human medicinal product in Germany, 
an application must be submitted to the BfArM or the PEI if it is serum, vaccine, 
antigen or blood preparation. The marketing authorisation is only valid for this 
particular national market. A national procedure is only possible when a 
centralised procedure is not compulsory (see 3.3.4).  
3.3.2 Mutual Recognition Procedure (MRP) 
The MRP is only feasible for products with an existing national MA in a Member 
State. The pharmaceutical entrepreneur may then choose to apply for MA in 
further Member States (Concerned Member State) using the identical application. 
The Member State in which the first marketing authorisation has been granted 
serves as the Reference Member State (RMS) and is responsible for issuing an 
Assessment Report that evaluates the safety, efficacy and quality based on the 
application. The Assessment Report is made available to the CMS. MA in the 
CMS is granted subsequently within 90 days, unless a serious risk to public health 
is identified and raised by the CMS. The identification of such a risk leads to a 
negotiation phase in the CMD(h) (Coordination Group for Mutual Recognition 
Procedures and Decentralised Procedures). When an agreement cannot be 
reached, the CMDH will evaluate the case by arbitration.8  
                                                 
8
 BfArM. MRP. [Accessed on: 26 Jun 2016]. 
http://www.bfarm.de/DE/Arzneimittel/zul/zulassungsverfahren/MRP/_node.html.  
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3.3.3 Decentralised Procedure (DCP) 
In contrast to MRP, the Decentralised Procedure is only possible if no national 
marketing authorisation has yet been granted and the pharmaceutical entrepreneur 
aims to obtain national marketing authorisations in several Member States. The 
pharmaceutical entrepreneur may choose the Reference Member State. An 
identical application is submitted simultaneously to the RMS and all other 
Concerned Member States. The RMS prepares a preliminary draft assessment 
report that can be commented by the CMS. In a second assessment phase, the 
report is evaluated within 90 days. Similar to the MRP serious risk to public 
health may be raised by any Member State involved in the procedure. The 
consequences are the same as in the MRP; the CMD(h) negotiates to find a 
mutually acceptable solution. When an agreement cannot be reached, the CMDH 
will evaluate the case by arbitration.9  
3.3.4 Centralised Procedure (CP) 
In most cases, the pharmaceutical entrepreneur is free to choose the procedure to 
gain approval for a product. However, for a number of products, the centralised 
procedure is required in the European Union. The products that are obligated to 
enter the market via the CP are defined in Regulation (EC) no. 726/2004. These 
include advanced therapy medicinal products and monoclonal antibodies as well 
as human medicines with novel agents for the treatment of AIDS, diabetes 
mellitus, cancer, neurodegenerative diseases, autoimmune diseases and other 
immune dysfunctions, viral diseases and orphan drugs. The centralised procedure 
differs from the other non-central procedures, as the same institution does not 
perform the scientific evaluation and the authorisation. A national competent 
authority in all non-centralised procedures conducts both assessment and 
marketing authorisation. In the CP, the application for MA is submitted to the 
European Medicines Agency (EMA) in London. The scientific committee for 
human medicinal products (CHMP) of the Agency carries out the assessment 
procedure. The CHMP consists of expert representatives from regulatory 
authorities of all Member States. The Committee will present their evaluation to 
                                                 
9
 BfArM. DCP. [Accessed on: 26 Jun 2016]. 
http://www.bfarm.de/DE/Arzneimittel/zul/zulassungsverfahren/DCP/_node.html.  
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the European Commission. Based on the findings of the EMA assessment the 
European Commission grants the marketing authorisation for the entire EEA. For 
products that have been approved under the CP, a European Public Assessment 
Report is published to inform the public in a summary about the product.10  
Table 1 Summary of authorisation procedures in Europe 
Procedure Available for MA valid in 
National 
Procedure 
All products not within the scope of 
Reg (EC) no. 726/2004 
Only Member State 
applied to 
MRP Products with existing MA in one Member State 
Several Member States, 
first in RMS, subsequently 
CMS 
DCP Products with no existing MA in 
any Member State 
Several Member States, 
simultaneously in RMS 
and CMS 
CP 
Mandatory for all products within 
the scope of Reg (EC) no. 
726/2004; 
Optional for other products 
Entire EEA 
 
3.3.5 Other marketing authorisation procedures 
Additionally to the procedures described above, other procedures exist according 
to Regulation (EC) no. 726/2004. These methods are only used for a small 
number of special cases. 
 Compassionate Use (Regulation (EC) no. 726/2004 Article 83) 
Compassionate use means the supply of an unlicensed product to a group 
of patients with serious or fatal diseases, for whom no satisfactory 
alternative therapy with an authorised product is available. The medicinal 
product is either subject of an application for a marketing authorisation or 
clinical trials. 
 
 Conditional marketing authorisation (Regulation (EC) no. 507/2006) 
The conditional marketing authorisation may apply in cases where there is 
a specific unmet patients’ medical need. Under these circumstances, a 
marketing authorisation can be granted before complete data are available. 
                                                 
10
 EMA. Central authorisation of medicines. [Accessed on: 26 Jun 2016]. 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000109.js
p. 
3 Regulations and authorisation of medicinal products 
 
 13 
 
It is presumed that the product has a positive benefit risk ratio that justifies 
the incomplete data on the clinical part of the application. The conditional 
MA is grated for one year and is subject to specific obligations. Clinical 
trials are required to be completed and after providing finalized data to 
support the positive benefit-risk-ratio, then the conditional MA can be 
transferred to a regular MA.11  
 
 Marketing authorisation under exceptional circumstances (Regulation 
(EC) no. 726/2004 Article 14 (8)) 
In specific cases where an applicant can demonstrate that it is not possible 
to assemble all required data on efficacy and safety under normal 
conditions for various reasons a MA with special obligations may be 
grated. Specific procedures regarding the safety of the product must be 
introduced. The authorisation is reviewed annually to assess the risk-
benefit ratio.12  
3.4 Limits and chances of the current regulations 
The goal of the European regulations is to achieve and maintain a harmonized 
system that provides a satisfactory framework for all stakeholders. The involved 
parties in the pharmaceutical regulations include many different groups such as 
regulatory agencies and authorities, pharmaceutical industry, development 
facilities, medical research, users and of course patients. The current regulations 
are designed to accomplish a balanced system in which the interests of all 
stakeholders are reflected. Thorough non-clinical and clinical testing of new 
products should protect patient safety. Nevertheless, innovation and new therapies 
shall be able to access the market in an appropriate timeframe so that investments 
in research and development pay off.  
                                                 
11
 EMA. Guideline on the Scientific Application and the Practical on the Conditional Marketing 
Authorisation for Medicinal Products for Human Use Falling Within the Scope of Regulation. 25 
Feb 2016 [Accessed on: 26 Jun 2016]. 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/03/WC50020
2774.pdf.  
12
 EMA. Guideline on procedures for the granting of a marketing authorisation under exceptional 
circumstances, pursuant to article 14 (8) of Regulation (EC) No 726/2004. 15 Dec 2005 [Accessed 
on: 26 Jun 2016] 
http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2
009/10/WC500004883.pdf  
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New developments in the medical field are however diverse and not always easy 
to predict. The ever-changing circumstances must therefore be carefully observed 
in order to keep the system and its stakeholders at balance. When new or better 
developments in science and medicine arise, they should be reflected in the 
legislation so that the legal situation is not lagging behind. The regulatory 
framework must therefore ensure that it will not inhibit the scientific progress, as 
this would have extensive consequences in the end for all stakeholders. Innovative 
therapies and procedures might have to face great difficulties in entering the 
market, despite a possible benefit, when it is outside the scope of the current 
regulation and the regulatory framework offers no approach for the particular 
innovation. If innovation cannot be sufficiently promoted, it will affect both the 
industry as well as the patients negatively. At the present pace of medical 
progress, for example in the field of genetic research, it can be expected that 
situations that are not covered by the legislation will occur more often. The 
current system will therefore probably turn out more often to be too rigid in 
future. For instance, the approval of free combination therapies is not possible 
with the present framework, which provides only the approval of individual 
substances, or a fixed combination of substances. More flexibility in the system 
could change the existing and future limitations and turn them into an opportunity. 
As the medical field advances, the regulatory framework should adapt to those 
developments as to maintain its high standards and to keep up with recent 
development as well as to offer solutions for different scenarios.  
New approaches to grant a more flexible system do not require an entirely new 
regulation. Including or adding new pathways can enhance the existing 
regulations. A first example that shows that the existing regulatory system has 
reached its limits but attempts to adapt to a more flexible approach has been 
presented in 2012. Adaptive licensing was introduced as a new pathway for 
marketing authorisation. The EMA has started a pilot project in 2014 for this new 
approach. This demonstrates that the EMA and other regulatory bodies have 
identified the necessity to extent the current system in order to meet new needs to 
close the gap between regulations and medical reality. 
The example of the adaptive pathway illustrates that new approaches can be set 
out based on the current system. Continuous development and adaptation of the 
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regulatory framework to the scientific opportunities is essential for all those 
involved. The current system gives the change to overcome many possible 
limitations and should overcome them in the interest of patients. 
3.4.1 EMA Adaptive Pathway (Adaptive Licensing) 
It becomes more and more obvious that the current marketing authorisation 
procedures do not fit for all scenarios. To keep up with the medical and scientific 
progress and with newly identified needs, it is important to adjust the regulatory 
framework to new conditions. One of the many limitations of the current 
frameworks is it binary decision process. Once a pharmaceutical obtains a 
marketing authorisation it becomes available to hundreds and thousands of 
patients more or less overnight while only being available to patient in trials under 
controlled conditions before. This problem and a possible solution scenario were 
addressed in 2012 by suggesting a new pathway: adaptive licensing.13  
Adaptive licensing was introduced as an approach to give more flexibility to the 
current system. In today’s regulatory system, safety and efficacy of a new 
pharmaceutical product is being tested and evaluated in randomized clinical trials 
(RCTs) under controlled conditions with a selected patient population. The results 
of the clinical trials are presented in the dossier to the authorities where safety and 
efficacy of the product are assessed to decide whether or not a marketing 
authorisation shall be granted. From the moment of marketing approval, the 
product’s safety and efficacy is considered appropriate when used within the 
scope of its label and the product is accessible for public and a wide group of 
prospective patients. Most of the patients that receive the product after 
authorisation are no longer part of controlled studies; the product is therefore used 
under everyday conditions with less restriction in the patient population than in 
the RCTs, including multi-morbid patients or patients receiving poly-medication. 
The effectiveness of the product (the beneficial effect of the drug), rare adverse 
reactions and possible new contraindications can be observed from this point of 
the drug’s life-cycle. Therefore, in reality the learning process about the medicinal 
product is not finished with the day of approval. New knowledge from broader 
                                                 
13
 Eichler H-G, Oye K, Baird LG, Abadie E, Brown J, Drum CL, et al. Adaptive licensing: taking 
the next step in the evolution of drug approval. Clin Pharmacol Ther. 2012;91(3):426–37. 
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usage may hence lead to label changes, such as restrictions or expansion of the 
indication. The day of approval is therefore rather a point in time (“magic 
moment”) in which the proof for safety and efficacy is considered sufficient even 
without having an absolute knowledge and new evidence will be gathered. Instead 
of having this “magic moment” in which the product switches from unapproved 
(still under investigation) to approved (safety and efficacy are considered 
satisfactory), adaptive licensing proposes a way to extend a product’s application 
sequentially to achieve several aims. First, patients with a high medical need 
would have earlier access to a therapy. Secondly, more evidence about the product 
under realistic and uncontrolled conditions is gained. Under the current regulatory 
framework, specific high medical needs are already taken into account. The 
conditional marketing authorisation (see 3.3.5) grants faster access to a new 
therapy in a field with a particularly high demand. Under the conditional 
marketing authorisation pathway, incomplete information regarding the clinical 
data requirements is available. However, the higher risk resulting from the lack of 
information is acceptable in circumstances with serious, life-threatening diseases 
with unsatisfactory therapeutic alternatives. Adaptive licensing aims to satisfy the 
unmet medical needs without granting a full marketing authorisation. After initial 
licensing, new data are collected for further risk assessment. To establish adaptive 
licensing, the development and licensing process needs to be determined in 
advance. In the current marketing authorisation procedure, clinical trials are 
performed under controlled conditions. Thus, all patients receiving the drug are 
monitored regularly. After receiving marketing authorisation, the number of 
patients in RCTs decreases soon, while the number of patients receiving the drug 
under real world conditions without any particular surveillance increases rapidly 
(see Figure 2 (a)). The time course is different for adaptive licensing. The process 
starts with patients in RCTs as well. Before starting clinical trials, it shall be 
planned with the regulatory authorities what data need to be obtained to allow a 
first risk and efficacy assessment. If the evaluation indicates a positive safety and 
efficacy balance, an initial license is granted. It should be clear that at the time of 
the initial license the clinical data are incomplete. Therefore, the initial license 
should be granted earlier than a normal marketing authorisation, as the RCTs are 
still on going. The initial license is not a full, normal marketing authorisation but 
allows the prescription of the drug under certain limitations to well-defined 
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patient populations outside of RCTs. These patients would still be under certain 
surveillance but are taking the medication under less controlled conditions. All 
patients, whether or not they are part of RCTs, are monitored, and the 
observations contribute to effectiveness and safety information. When data from 
clinical trials and observational studies are complete to allow a concluding 
evaluation a full authorisation for the product is issued (see Figure 2 (b)). The 
current authorisation process and proposed adaptive licensing are compared in 
Figure 2, showing the patient groups of the process and the period.  
 
 
Figure 2 Time course of (a) current marketing authorisation and (b) adaptive licensing. The time 
from start of RCTs to initial license in the adaptive licensing model is shorter than in the current 
process. Patients outside of RCTs gain earlier access to the product in AL before a full license is 
issued. Current MA process only includes patients in RCTs only in the pre-licensing phase leaving 
effectiveness studies to the post-licensing phase.13 
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The definition for adaptive licensing proposed by Eichler et al is as follows: 
Adaptive licensing is a prospectively planned, flexible approach to 
regulation of drugs and biologics. Through iterative phases of evidence 
gathering to reduce uncertainties followed by regulatory evaluation and 
license adaptation, AL seeks to maximize the positive impact of new drugs 
on public health by balancing timely access for patients with the need to 
assess and to provide adequate evolving information on benefits and 
harms so that better-informed patient-care decisions can be made.13 
The EMA adopted the proposed approach using the basis of currently existing 
regulatory procedures. A pilot project started in 2014 under the name adaptive 
pathways to demonstrate that the approach considered the drug’s life-span from 
clinical development, approval, reimbursement and clinical practice.  
The concept of adaptive pathways foresees either an initial approval in a 
well-defined patient subgroup with a high medical need and subsequent 
widening of the indication to a larger patient population, or an early 
regulatory approval (e.g. conditional approval) which is prospectively 
planned, and where uncertainty is reduced through the collection of post-
approval data on the medicine's use in patients.14  
EMA is now gathering experience on the pathway and tries to identify eligible 
candidates for the program. The Agency has released a list of criteria for potential 
candidates who shall provide: 
 an iterative development plan, either by gradual expansion of the target 
population (e.g. starting from a population with a high medical need) or by 
progressive reduction of uncertainty after initial authorisation, based on 
surrogate endpoints; 
 an ability to engage HTAs and other downstream stakeholders, with 
proposals for how their requirements can be met; 
 proposals for the monitoring, collection and use of real-world post-
authorisation data as a complement to randomised clinical trial data.14 
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 EMA. Adaptive pathways. [Accessed on: 26 Jun 2016]. 
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The next years will show if the adaptive pathway will become a new authorisation 
approach and will be implemented in the regulations. The approach certainly 
demonstrates the need for new and innovative ways to adapt the regulatory 
framework to modern experience and new knowledge in medicine. When the 
medical need gets more and more specific, pathways to satisfy these specific 
requirements are necessary. Adaptive licensing is one of those pathways, but 
others are needed for different situations. Therapeutic concepts are such a new and 
different approach that would allow more flexibility in the field of combination 
therapies. 
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4 Therapeutic concepts: Proposal of a new regulatory approach 
for combinations 
4.1 Definition and scope of therapeutic concepts 
The introduction of the Adaptive Pathway shows that the regulatory framework 
for drug authorisation needs constant development and changing to adapt to new 
challenges.  
There are several other aspects in drug authorisation, that are reflected 
unsatisfactory in the regulatory framework. In the current status of drug 
development and drug approval, only one agent at a time is reviewed and 
approved by authorities. Yet, it is common knowledge that for certain diseases a 
variety of drugs and medical devices are used in combination to treat a condition. 
Combinations of medicinal products are very frequently used in the medical 
practice but the legislation for combinations is lagging behind when compared to 
single drug authorisation. Combinations of medicinal products have a long 
history, and it is likely that with the current research the use of medical 
combinations will even extent. With the evolution of personalized medicine, 
research is just beginning to recognize the many different biological and genetic 
aspects of diseases. This knowledge can be used in drug development and therapy. 
Having a more detailed understanding of the cellular pathways provides better 
chances to target drug therapy. Because the body is a complex biological system, 
it is in many diseases not enough to inhibit only one cellular pathway, as 
alternative routes can be activated as a response to such inhibition that leads to 
therapy resistance. To develop targeted therapy a complete understanding of the 
biochemical response to drugs and disease is needed. Then, drug combinations 
can be designed to address multiple cellular pathways and resistance mechanisms. 
Personalized medicine and genomic research are an important part of the 
development towards the targeted drug combination therapy.15 Today, some of the 
most serious diseases, such as Hepatitis C, HIV infections and many types of 
cancer require a combination of drugs for the treatment. Other treatments rely on 
                                                 
15
 Woodcock J, Griffin JP, Behrmann RE. Development of Novel Combination Therapies. N Engl 
J Med. 2011;364(11):985–7.  
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the outcome of a diagnostic test. The diagnostic test should hence be considered to 
be part of the treatment regime.  
Therefore, a gap between treatment reality, research and approval practice exists. 
The limits of single drug authorisation are reached. New pathways for the 
authorisation of combinations need to be introduced. The next logical step in the 
regulatory framework is the co-approval of combination therapies based on 
targeted approaches, which so far does not exist. The approach introduced in this 
thesis recommends this additional new way of drug approval to overcome this 
gap. The development and approval of novel therapeutic concepts would be a 
consistent step towards a better health care. A clear regulatory pathway towards 
an approval of drug combinations could help agencies, health care professionals 
and patients to gain safer therapies and clear recommendations for medical 
practice.  
To distinguish between an approved combination regimen and the frequently used 
term “combination therapy” that refers to a general therapy consisting of a therapy 
with multiple medicinal products or other treatment options, a new term is 
introduced for the approved combination therapy: “Therapeutic concept”.  
The definition for a therapeutic concept as it is introduced and used in this work is 
the following16: 
Therapeutic concept: 
A therapeutic concept is the approval of a treatment regimen, 
consisting of two or more, marketed or not yet marketed, 
medicinal products or one or more medicinal products and a 
companion diagnostic/medical device, if it is required for a safe 
and effective use of the regimen, that have been developed and 
studied together for a specific condition and patient population. 
 
                                                 
16
 Krollmann KB, Schweim HG. Zulassung von „therapeutischen Konzepten“ / Der nächste Schritt 
zu einer „personalisierten“ Medizin. pharmind. 2015;77(5):650–3. 
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A therapeutic concept therefore clearly differs from the other options for drug 
combination (such as fixed combinations) which are introduced in Chapter 4.2. 
Unlike guidelines, authorisation of therapeutic concepts would not be a 
recommendation based on experience but is a clear statement that this 
combination has been studied as an intended combination.  
The following options for combinations to fall under the scope of therapeutic 
concepts exist: 
1. Combination of two or more medicinal products 
2. Combination of one or more medicinal product with a companion 
diagnostic. 
The drugs used in a therapeutic concept shall not be a fixed combination, nor 
shall they be required to come in one single package but can be marketed and 
dispensed separately.  
The combination used in a therapeutic concept shall be intended to be adjusted to 
individual patient’s needs. The separated administration of the components 
provides the opportunity to administer the medication in an appropriate dosage to 
prevent side effects and increase efficacy and compliance. Individual dosing can 
be handled more easily when the components are not part of a fixed 
combination.16,17  
As companion diagnostics are nowadays often a vital tool for diagnosis and 
selection of treatment, therapeutic concepts shall provide the opportunity to 
include companion diagnostics in an approved therapy. That means that two 
products which currently fall under different legislations (medicinal products and 
medical devices) would be combined for specific cases under the medicinal 
product legislation.  
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4.2 Fixed combinations and combination packs 
Now, several possibilities provide assistance when and how drug combinations 
are indicated. These are 
 Medical guidelines 
 Combination packs 
 Fixed combinations 
While medical guidelines are usually initiated by medical societies and are based 
on review of clinical data, combination packs and fixed combinations are 
regulatory terms and describe pharmaceutical products approved by a competent 
authority.  
Development and importance of medical guideline are outlined in Chapter 4.3. 
In the definition of the EMA, a combination pack  
„consists of more than one medicinal product, or more than one 
pharmaceutical form of the same medicinal product, presented under a 
single (invented) name and in a single product package (e.g. box, blister 
pack), where the individual products/forms are intended for simultaneous 
or sequential administration.”18  
An example for a combination pack is ZacPac, which consists of three different 
active substances, namely pantoprazol, amoxicillin and clarithromycin.19 ZacPac 
is indicated for treatment of Helicobacter pylori infection (refer to Chapter 4.4.2). 
The combination pack is a comfortable choice for the patient, as the right amount 
of tablets is provided for the treatment unit and it is less likely for the patient to 
forget taking one of the tablets, thus combination packs can improve the patient 
compliance. The downside of such combination packs is the relative high price 
compared to generics of the single active substance.  
                                                 
18
 EMA. Guideline on the non-clinical development of fixed combinations of medicinal products. 
CHMP/EWP/240/95 Rev. 1. 19 Feb 2009 [Accessed on: 26 Jun 2016]. 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC50000
3686.pdf. 
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 SmPC. Takeda ZacPac. March 2016 [Accessed on: 26 Jun 2016]. 
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In contrast to a combination pack, a fixed combination is defined as the 
combination of active substances within a single pharmaceutical form of 
administration. The EMA states  
“the proposed combination should always be based on valid therapeutic 
principles. Fixed combination medicinal products have been increasingly 
used to benefit from the added effects of medicinal products given 
together. In addition, it is necessary to assess the potential advantages 
(e.g. product rapidly effective, higher efficacy or equal efficacy and better 
safety) in the clinical situation against possible disadvantages (e.g. 
cumulative toxicity), for each fixed combination product and for each dose 
of the fixed combination product. Potential advantages of fixed 
combination products may also include the counteracting by one 
substance of an adverse reaction produced by another one and the 
simplification of therapy.”18 
Fixed combinations are found commonly for many different indications. 
Cardiovascular diseases often require multiple active substances, and for patient 
convenience many fixed combinations are on the market in this area (e.g. Atacand 
plus with candesartan and hydrochlorothiazide20). To cover all the individual 
needs of the patients a wide range of different combinations with different content 
of active substances need to be marketed. Even though these combinations are 
easy to use for the patient, as they only need to take one rather than two or more 
pills a day, fixed combinations are as inflexible as their name already indicates. A 
change in the dosage of one active substance, for example, is quite complex to 
implement. There are also certain restrictions and limits to fixed combinations. 
They can only be developed under certain conditions, for example, only if the 
active ingredients can be taken concurrently. Furthermore, the duration of action 
of each active substance should correspond with the administration interval. 
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4.3 Medical guidelines 
Besides the regulatory possibilities for combinations of medications such as fixed 
combinations and combinations packs other non-regulatory approaches exists that 
provide guidance for the use of combinations in specific disease patterns, namely 
medical guidelines (German: “Leitlinie”). Medical guidelines support physicians 
in the therapeutic decision making by suggesting therapeutic approaches that can 
include combinations based on evidence and experience in the medical field. The 
guidance given in published medical guidelines can be regarded as an aid and 
necessity as to close the existing gap between the limited regulatory combination 
possibilities and medication practice, even though this is not their main purpose. 
However, the information presented in medical guidelines cannot be viewed 
equivalent to authorised combinations from the legal perspective.  
The primary objective of medical guidelines is the improvement of quality in 
health care by applying evidence based and economically appropriate therapies. 
They are created to present the current state of scientific knowledge to optimize 
the medical care. Furthermore, they should help avoid unnecessary and obsolete 
methods of medical practice. Another task is to inform the public.21  
At first, the term “medical guideline” otherwise also called “clinical practice 
guideline” (hereafter referred to as guidelines), needs to be defined. The 
Association of the Scientific Medical Societies in Germany (Arbeitsgemeinschaft 
der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF)), founded in 
1962, is the publisher of many medical guidelines and represents more than 160 
medical societies in Germany. The association gives advice about fundamental 
medical questions, not only to their member organizations, but also regarding 
political concerns and represents Germany in the WHO Council for International 
Organizations of Medical Sciences CIOMS.22 The question of medical guideline 
definition is answered as following:  
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 Ollenschläger G. Leitlinien in der Medizin – scheitern sie an der praktischen Umsetzung ? Der 
Internist. 2001;42(4):473–83. 
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“Guidelines are systematically developed statements reflecting the current 
state of knowledge and meant to support doctors and patients in making 
decisions concerning appropriate care for specific health problems. 
Guidelines are important and effective instruments for quality development 
in health care. Their primary objective is to improve medical care by 
disseminating current knowledge. Guidelines […] formulate clear 
recommendations for treatment backed up by a clinical weighting of the 
power and applicability of the study results. Guidelines can be understood 
as "treatment and decision corridors” which can or should be deviated 
from in justified cases.”23  
Guidelines are developed to improve health care and describe the best clinical 
practice. Evidence-based medicine is one of the main principles that ought to be 
reflected. Clinical practice guidelines are part of all fields of medical practice. It 
begins with how to diagnose patients, which test and screening might be 
necessary. They might then be helpful to establish a patient’s medical therapy, 
either by drugs, surgery or other possibilities. Moreover, guidelines may offer 
advice, on how surgical procedures can be performed, how long patients should 
stay in hospital and many other questions that rise in clinical practice.24 However, 
guidelines are not intended to be used as a “cookbook” that provides every step in 
patient care. It is the clinician’s responsibility to interpret the use of the guideline 
for an individual patient.  
Medical guidelines aim to help several stakeholders. First, they are one of the 
most important sources for doctors and health care professionals for decision-
making. Especially for the most common diseases, such as asthma, high blood 
pressure or diabetes, guidelines are a great tool, as they mostly consider the 
current status in medicine. Guidelines are furthermore meant for the public to 
inform about therapy options. Patients or other interested persons can access most 
guidelines on the internet free, giving them a chance to discuss those options with 
their physician and informing them about treatment alternatives. The third 
                                                 
23
 AWMF. Introduction: What are guidelines? In: AWMF Guidance Manual and Rules for 
Guideline Development. p. 5. Version 1.0. 06 Nov 2012 [Accessed on: 26 Jun 2016].  
http://www.awmf.org/leitlinien/awmf-regelwerk/awmf-guidance.html.  
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 Woolf SH, Grol R, Hutchinson A, Eccles M, Grimshaw J. Clinical guidelines: potential benefits, 
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stakeholder for whom guidelines are of great interest is the health care system. 
Guidelines are always intended to present economic aspects of different treatment 
or diagnosis methods as well. A more detailed overview about potential benefits 
and harms is given in subsection 4.3.1. 
However, despite all good intentions guidelines are repeatedly criticized. It is 
questionable whether the ambitious goal of improvement of care, consistency, 
efficiency and cost reduction are actually achieved. A poor implication into 
practice often stands in the way.25 A proper implication of high quality guidelines 
in the health care sector over the next years is therefore an important task.26 
Furthermore, there is criticism that the guidelines assume an ideal, average 
patient, not an individual patient where certain conditions are to be considered, 
such as co-medication, age and medical history.27 The number of guidelines with 
a high degree of systematic development (S3) is small. They usually only exist for 
very common diseases since evidence for less frequent illnesses is often not 
sufficient for a systematic guideline process. The financial aspect is certainly a 
reasonable approach, but therapy should not be withheld from patients for 
economic reasons. The right balance between cost-effectiveness and the selection 
of effective interventions must be found.28  
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4.3.1 Benefits and harms of medical guidelines 
As described above, guidelines are meant for different stakeholders in the health 
care sector, most importantly health care professionals, physicians in particular, 
patients and payers. The different impact, both positive and negative to these 
groups will be reviewed in this part. 
Health care professionals 
There are various potential benefits and harms for physicians in medical 
guidelines. The most obvious benefit for health care professionals is a clear 
guidance on how to handle specific situations and illnesses. A guideline of high 
quality can most certainly improve quality of care when a clear decision-making 
pathway is defined. Available treatments should be compared and distinctions 
among interventions should be explained. Doctors can learn about new or more 
effective interventions, giving their patients the best possible care while making 
cost-effective decisions, too. Furthermore, attention is called to treatment 
alternatives, which are outdated, ineffective or harmful, obsolete medication or 
surgery creates high costs in the health care system and makes patients suffer 
longer from their illness, due to higher failure rates, side effects, and longer 
hospitalization. Consequently, guidelines are an essential tool to keep physicians 
and other health care professionals updated on the current medical evolvements. It 
is nonetheless of uttermost importance that doctors do not only rely on the actual 
guideline, but also keep themselves posted by reading other medical literature, as 
one must not expect that guidelines always present the current status. Guidelines 
need to be updated, in some cases more frequently than in others, and it has to be 
kept in mind, that a six months old guideline can already be out-of-date. Health 
care professionals have to be able to independently evaluate the information given 
in the guideline to identify an obsolete or flawed one. Only a vivid dialogue 
between guideline developers, health care professional and other stakeholders can 
preserve high quality guidelines. Additionally, the guideline developing progress 
and discussion helps to find gaps in evidence and assess the quality of studies that 
are included in the guideline. If lack of evidence is found, efforts can be made to 
close the knowledge gap and improve health care.  
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Guidelines are a good basis for doctors to justify their decision and may 
strengthen their position towards patients, payers and administrators. In case of 
being charged with error of treatment, guidelines can provide legal protection, if 
used properly. (For further legal considerations, see Chapter 4.3.3) 
Despite all the benefits, guidelines are not always easy to handle. Implementation 
of the given medical advice is described challenging by some physicians, they 
find guidelines time-consuming and some guidelines cannot be simply realized in 
medical practice. Physicians are moreover confronted with contradicting 
guidelines when working in fields where several aspects need to be considered 
before starting therapy, such as cardiovascular diseases, which are often 
associated with metabolic syndrome. It may occur that different scientific 
societies give opposing opinions on how an illness should be treated.  
Guidelines may have a negative impact on reimbursement practice. Payers may 
not cover interventions, which are not mentioned in a guideline, for whatever 
reason, anymore. For doctors, who do not have any alternative options for a 
patient, this might be a significant hurdle.24 
Patients 
One of the main and most important benefits for patients that guidelines provide is 
a better treatment outcome. When physicians follow the right recommendations in 
the guideline, treatment will be more likely to be successful due to choosing a 
therapy that has proofed to be the best available option. In a high quality 
guideline, different therapies have been compared in numerous patients giving 
enough evidence to draw a conclusion. On the other hand, treatment options that 
have proven to be inefficient are discarded, sparing patients unnecessary therapy, 
which would only result in side effects and time loss without improving the 
patient’s health. The intention of guidelines is to harmonize the treatment of a 
certain disease in a way that patients, regardless of where they are treated, would 
be cared for in an equal matter. This ambition is more difficult to reach. While it 
may be possible to harmonize therapy in one region or even one country it is 
almost impossible to achieve harmonization on an international level, keeping in 
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mind that different drugs are on the marked in every country and the medical 
background and traditions vary.  
Another benefit that medical guidelines offer to patients is drawing attention to 
new findings. If a new method or drug is highly recommended by a guideline, this 
can help patients gain access to those, since it becomes more likely for them to be 
reimbursed. 
Patients are given the opportunity to get informed about their care by using 
patient’s leaflets that are usually handed out with a clinical practice guideline. 
This seems to be a challenge for patients to learn about their conditions and the 
opportunities that are available. It might help involve the patient in the treatment 
process, which can improve the therapeutic success. Then again, the information 
given to the public might as well cause confusion. For instance, when doctors do 
not chose the best-recommended therapy for any reason, perhaps because the 
patient has a specific condition that makes a less recommended treatment the 
better option in this case, the patient might not understand this. This can cause 
distrust and in consequence leads to worse results.  
However, confusion and distrust are not the major problem for the patient. The 
greatest harm lays in outdated or inflexible guidelines. Outdated guidelines that do 
not represent the current medical knowledge result in a less effective, suboptimal, 
or even worse, harmful therapy. Guidelines of low quality might offer wrong 
recommendations, which is obviously a risk. A further threat for the patients is the 
inflexibility of some clinical practice guidelines or doctors that take the 
recommendations as a one-size-fits-all approach. Leaving out individual 
characteristics of a patient by strictly following a guideline from top to bottom 
will give some patients an inappropriate care.24 
Health care system 
It has already been described that guidelines can make new interventions the best 
available care, replacing other older and ineffective approaches. Reimbursing the 
best care helps the health care system by granting the patients access to superior 
treatments thus improving public health. The health care system mainly benefits 
from the economic point of view. Guidelines can standardize health care and 
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suitable implementation of guideline recommendations in clinical practice reduces 
costs. Of course, cost reductions can only be realized with systematically 
developed guidelines in which economic matters and medical issues are equally 
included. Therefore, payers should verify a guideline’s content before reimbursing 
new services. Otherwise, important resources and money might be wasted.24 
 
Table 2 Summary of potential benefits and harms of medical guidelines 
 Benefits Harms 
Health care 
professionals 
Clear guidance for clinical 
decision-making 
 
Flawed or outdated guidelines 
with incorrect information 
 
Improved quality of care Time consuming use 
Attention for harmful or 
ineffective treatments 
Difficult to implement when 
guideline does not meet clinical 
demands 
Legal protection in some 
respects 
Reimbursement questionable 
when intervention is not 
recommended 
Patients 
Improved health care outcome Inflexibility 
Standardized care Treatment with incorrect or 
outdated recommendations 
Information Disturb patient-doctor 
relationship 
Heath care 
system 
Cost reduction Waste of resources 
Standardized care  
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4.3.2 Development and quality of guidelines 
Guidelines are “systematically developed statements”24 and are to be developed 
according to standardized principles. The AWMF has published a guidance to 
help developers maintain quality standards based on DELBI and AGREE criteria. 
DELBI (Deutsches-Leitlinien-Bewertungsinstrument, German tool for appraisal 
of clinical practice guideline) is the German adaption of the international AGREE 
(Appraisal of Guidelines for Research and Evaluation) instrument that is a tool for 
the assessment of medical guidelines. DELBI and AGREE can be used by 
developers and users to evaluate the quality of a clinical practice guideline.29  
According to the AWMF guidance, development or revisions of guidelines 
usually begins with finding a subject or scope. The subject of a guideline should 
always be of importance for the health care sector. The selection of subjects 
should be comprehensible and of justified medical necessity. Various reasons can 
explain the need for a guideline. These include for instance the prevalence of a 
certain health care aspect, potential of improvement or optimization and great 
differences in care. Even when an illness’s prevalence is not very high, the need 
for a new guideline may be justified by a poor standard of care. Furthermore, 
economic factors as well as ethical and social aspects play a role in the selection 
process. New technologies can be introduced by guidelines.23 The guideline 
should always have a clear clinical question that it intends to answer without 
having a scope that is too broad. It needs to be defined which topics ought to be 
covered by the guideline in order to give reasonable and practical advice that can 
be implemented in the clinic.  
The groups involved in the guideline working process should represent as many 
appropriate stakeholders as possible. This can include several organizations, 
scientific medical societies as well as users and patients of the target audience. 
Professionals who are familiar with the methodological approach and evidence-
based medicine (EBM) are an important part of the development group. In 
general, a multidisciplinary group is more likely to prevent biases that might 
occur in imbalanced groups; moreover, this later on improves the chances of 
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 The AGREE Collaboration. Development and validation of an international appraisal instrument 
for assessing the quality of clinical practice guidelines: the AGREE project. Qual Saf Health Care. 
2003;12(1):18–23. 
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better implementation and acceptance.30,31 From the beginning, the group should 
be aware of the systematic process it chooses. In Germany, different 
classifications are known that describe the degree of systematic development: S1, 
S2k, S2e and S3. S3 guidelines present the highest systematic development, 
whereas S1 is the lowest that is formed by expert recommendation without a 
systematic research. S2e guideline (“e” = evidence) is developed using systematic 
research, while S2k (“k” = consensus) is based on a structured consensus of a 
representative body. The highest standard S3 combines all elements; it may 
include expert opinions but a systematic performed research and formal consensus 
is compulsory.32 The choice of classification for which the guideline is aimed is 
dependent on how much effort is suitable and implementable.  
 
Table 3 S-classification of medical guidelines according to AWMF. 
S1 S2k S2e S3 
Informal consensus 
or expert 
recommendations 
Consensus-based Evidence-based 
Evidence- and 
consensus based 
low  
degree of systematic 
development 
high 
 
To ensure high quality, it is suggested to hold on to DELBI and AGREE 
specifications for the actual development process. For S2e and S3 a systematic 
review of available literature is inevitable. Literature includes not only clinical 
trials and studies and their reviews and meta-analysis, but also other guidelines to 
screen for possible contradictions or adaptions that can be made. The literature 
obtained by research is to be categorized by level of evidence with a classification 
                                                 
30
 Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF)-
Ständige Kommission Leitlinien. Zusammensetzung der Leitliniengruppe: Beteiligung von 
Interessengruppen. In:  AWMF-Regelwerk Leitlinien. p. 10. 1st edition. 09 Nov 2012 [Accessed 
on: 26 Jun 2016]. http://www.awmf.org/leitlinien/awmf-regelwerk.html.  
31
 Shekelle PG, Woolf SH, Eccles M, Grimshaw J. Clinical guidelines: developing guidelines. 
BMJ. 1999;318(7183):593–6. 
32
 Muche-Borowski C, Kopp I. Wie eine Leitlinie entsteht. Z Herz-Thorax-Gefäßchir. 
2011;25(4):217–23. 
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system (i.e. levels of evidence of Oxford Centre for Evidence-based Medicine33). 
According to the evidence situation the strength of the guideline recommendation 
must be indicated, for example by using the AWMF code, in which A stands for a 
strong recommendation, B representing a recommendation (weaker compared to 
A) and 0 meaning recommendation open.23 
4.3.3 Legal considerations 
In this section, mainly the German legislation will be reviewed. Nevertheless, the 
findings presented here will most likely apply for most legal environments. 
A guideline, by definition, is not legally binding and following is not mandatory. 
In German: 
“Die „Leitlinien“ sind für Ärzte rechtlich nicht bindend und haben daher 
weder haftungsbegründende noch haftungsbefreiende Wirkung.“34  
This also applies to medical guidelines. The AWMF states that guidelines are not 
legally binding for health care professionals and therefore have neither liability 
nor liability claim liberating effect.  
Guidelines have different impact on social law and liability law. The question is 
whether guidelines actually present something new looking from a legal 
perspective regarding liability or if they are rather a methodological approach to 
describe the duty of care according to German Civil Code Section 276 (§ 276 
BGB).35 Guidelines are to be understood as guidance, they cannot adequately 
determine an error in treatment.28,36 An error in treatment is characterized by the 
deviation from the standard of care at the particular time of the patient’s 
treatment.37 Guidelines may be useful for determining those standards, however, 
are often not sufficient in a particular case. Guidelines may be outdated, may not 
apply to the corresponding case or do not present all known treatment alternatives; 
                                                 
33
 Centre for Evidence-based Medicine. Oxford Centre for Evidence-based Medicine - Levels of 
evidence (March 2009). [Accessed on: 26 Jun 2016] http://www.cebm.net/index.aspx?o=1025.  
34
 AWMF. Leitlinien. [Accessed on: 2015 Dec 06]. http://www.awmf.org/leitlinien.htm. 
35
 Ratzel R. Qualitätssicherung, Leitlinien und Recht. Geburtsh Frauenheilk. 2006;66(S 2):Q8–
Q14. 
36
 Dierks C. Juristische Implikationen von Leitlinien. Dtsch Med Wochenschr. 2003;128:815–9. 
37
 Bundesministerium für Gesundheit. Behandlungsfehler. [Accessed on: 26 Jun 2016]. 
http://www.bmg.bund.de/themen/praevention/patientenrechte/behandlungsfehler.html. 
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therefore, expert opinion discussing the guideline is usually necessary in court.38 
This is confirmed in a judgment of the higher regional court (Oberlandesgericht 
(OLG)) Naumburg, Germany. The Court does not see guidelines as binding 
instructions, due to differences in quality, legitimacy and topicality. They cannot 
represent the individual treatment case.39 The Federal Court of Justice 
(Bundesgerichtshof (BGH)) came to a similar decision in 2008, indicating that 
guidelines are non-binding.40 Likewise, the OLG Köln saw a deviation from a 
guideline not necessarily as an error in treatment; the individual case must be 
considered.41 A violation of guidelines is also no grave error in treatment, and 
therefore does not necessarily shift the burden of proof away from the 
complainant.42 Nevertheless, it will be difficult in some cases to justify the 
deviation from a high quality guideline, thus meaning for doctors to make sure a 
current, appropriate guideline is always used. If not, it should be well documented 
why other measures have been taken. Some experts claim that the uncertain legal 
status of guidelines leads to a lower acceptance of those in the medical 
profession.21 Then again, it should be warned against trying to establish guidelines 
as legal standards. This would restrict the freedom of medical therapy and cause 
uncertainty.43 The character of an orientation aid, as defined by the AWMF, 
should be retained since the quality differences are still striking 
Legal liability aspects affect not only physicians and patients. The guideline 
development process requires greatest care and skills. Nevertheless, there is no 
guaranty for an absolutely accurate guideline despite all control. Critical questions 
concerning the development course arise: 
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 Hart D. Ärztliche Leitlinien - Definitionen, Funktionen, rechtliche Bewertungen. Medizinrecht. 
1998;1:8–16. 
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 OLG Naumburg. Urteil vom 19.12.2001; Az: 1 U 46/01. 
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 BGH. Beschluss vom 28.03.2008; Az: VI ZR 57/07. 
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 OLG Köln. Urteil vom 18.08.2010; Az: 5 U7/10. 
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 OLG Stuttgart. Urteil vom 22.02.2000; Az: 14 U 62/00. 
43Clade H. Medizinische Leitlinien: Entscheidungshilfen für Arzt und Patienten. Dtsch Arztebl. 
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 Who initiated the clinical practice guideline process and selects those 
involved in the discussion and creation? 
 Which criteria determine content and evidence? 
 How is the development financed?  
 Are (employees of) pharmaceutical companies allowed to participate 
financially or through collaboration? 
 Who is liable for the accuracy, e.g. in the event of a faulty dosage? 
 Can companies sue guideline developers should their drug or therapy not 
be included despite existing evidence? 
In general, authors of a guideline or the scientific society can be sued for wrong 
statements and conclusions. The AWMF can be made responsible for dispensing 
flawed guidelines and should withdraw questionable guidelines from circulation, 
but again, liability is a case-by-case decision. These considerations should be kept 
in mind as criticism of guidelines comes up from time to time. For instance, 
questions about pharmaceutical industry involvement recently hit the lay press, 
when the Spiegel magazine reported that new drugs are added too quickly to a 
guideline caused by industry pressure.44 The producers of guidelines need to be 
aware of their important yet responsible task, which is a great tool of information 
for all health care stakeholders when done in the right way. 
Despite the non-binding nature of guidelines, they are referred to in several 
sections of SGB V and are thus represented as an important part of social 
legislation. This includes, for instance, the general practitioner-centred care, in 
which treatment is to be carried out according to evidence-based guidelines for 
primary care that have been tested in practice (§ 73b Abs. 2 Nr. 2 SGB V). 
Furthermore they are mentioned in § 137f Abs. 1 Nr. 3 and Abs. 2 Nr. 1 SGB V 
(structured treatment programs for the chronically ill) as well as § 139a Abs. 3 
Nr. 3 SGB V (IQWiG will evaluate evidence-based guidelines for the 
epidemiologically important diseases). As already discussed, guidelines can 
influence social law by initiating reimbursement of services and thus serve as a 
control tool in health care. However, there is only an indirect and no formal 
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 Kuhrt N. Pharmaindustrie soll Leitlinien beeinflusst haben. In:  Spiegel Online. 24 Mar 2013 
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connection between guidelines and the services and treatments reimbursed by the 
GKV (statutory health insurance). Quality and effectiveness of services have to 
comply with the general state of medical knowledge and take account of medical 
progress (§ 2 Abs. 1 S. 3 SGB V) but must also be practical and economical (§ 12 
Abs. 1 S. 1 SGB V, § 70 Abs. 1 SGB V). Guidelines can provide information 
about these terms and start a reimbursement discussion. 
In conclusion, medical guidelines present a good orientation for all stakeholders 
but are also often reason for criticism and uncertainty. They may be a helpful aid 
regarding the choice of combinations of medicinal products. However, not every 
combination described in guidelines is actually advisable. More reliability for 
doctors therefore would be desirable and could be created by the approval of 
therapeutic concepts in some cases. 
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4.4 Targeted drug combinations 
The combination of drugs is as old as medicine itself. It is commonly 
acknowledged that combinations are the better choice compared to monotherapy 
in many diseases. Combinations therapy is in some diseases even the standard of 
care and monotherapy in these cases would be considered as treatment error. 
These therapies with several pharmaceuticals are often found in diseases where 
the patient population is clearly defined.  
Some classic examples of these diseases with combination therapy are described 
below. The reasons why drug combinations in many diseases are the better 
alternative are diverse. The most common reasons include 
 Biological rational 
A biological rational could be the prevention of resistance in antibiotic 
therapy. Serious diseases caused by bacteria, such as tuberculosis, with a 
high risk of resistance are therefore treated with several antibiotic agents 
to minimize the risk (see chapter 4.4.1). Other biological rationales are for 
example the addition of an agent to a drug that would prevent side effects. 
 Differentiation in the cause of the disease 
A disease can have different causes but cause the same symptoms. 
Gastritis, for example, can be caused either by gastric hyperacidity or by 
the bacterium Helicobacter pylori. The treatment of the disease’s origin 
results in different treatment of the symptoms, and requires in case of H. 
pylori infection a combination of several agents (see chapter 4.4.3) 
 Stratification or subgroup analysis 
Subgroup analysis of a certain (combination) therapy might reveal that the 
therapy works especially well in a particular patient subgroup. This 
happened in case of the so-called “race-drug” BiDil (chapter 4.4.3). 
This shows that a need for regulation in the field of combinations thereof. The 
examples indicate that the need for regulation in the field of combinations is 
obviously present.  
4 Therapeutic concepts: Proposal of a new regulatory approach for combinations 
 
 39 
 
4.4.1 Tuberculosis 
Worldwide, tuberculosis (TB) is one of the most common infectious diseases and 
the second leading cause of death caused by infections. The WHO indicates 1.5 
million deaths by tuberculosis and 6 million new cases in 2014.45 One-third of the 
world’s population is estimated to be infected with TB; however, only 10% of 
infected people develop the disease.46,47 The causative agent of tuberculosis is 
mainly Mycobacterium tuberculosis, which was discovered by Robert Koch in 
1882.48 M. tuberculosis is a rod-shaped bacterium that has a relatively long 
generation time of 18-24 h. The bacterium has the ability to become dormant in 
macrophages, a state in which it does not dived and has low metabolic activity. It 
is also resistant to chemotherapy in this state.49 The cell wall of M. tuberculosis is 
quite unusual. Staining using the Gram technique is of little avail, an acid-fast 
stain can be used instead. Mycobacteria resist Gram staining as their cell wall 
contains high amounts of branched lipid substances that are linked to 
arabinogalactan forming mycolic acids. The characteristic cell wall structure is 
responsible for the bacterium’s resistance against most known anti-infective 
medications.50 As an obligate intracellular pathogen, M. tuberculosis prefers tissue 
with high oxygen levels. Hence, infection of the lungs is most common.51 
Symptoms of pulmonary tuberculosis include chest pain and prolonged cough, 
which may contain blood. In a smaller number of cases, TB may also occur in 
other parts of the body (extrapulmonary tuberculosis). Fever, weight loss and 
night sweats are general symptoms of TB infection.51,52 TB is transferred via 
droplet infection. Microscopy of active TB patients’ sputum is used to diagnose 
the presence of the bacterium. 
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 WHO. Introduction. In: Global tuberculosis report 2015. p. 1. [Accessed on: 26 Jun 2016] 
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Therapy of tuberculosis always aims to minimize the risk of resistance. Therefore, 
treatment with a combination of antibiotic substances is of utmost importance as 
well as the patient’s compliance to therapy. Treatment with only one agent would 
select mutated resistant pathogens. In combination therapy, the drugs used in the 
regimen have different modes of action to target all M. tuberculosis populations. 
Isoniazid and rifampicin are bactericidal against replicating bacteria in neutral pH. 
Rifampicin also has a sterilizing effect on pathogens with very low metabolic 
activity that only have very short metabolically active phase. Pyrazinamide acts 
on slowly proliferating pathogen located in acidic environment. Ethambutol 
diminishes the risk of resistance.53  
In uncomplicated cases, a six-month therapy as shown in Table 4 is the standard 
of care. For the first two months four substances are administered daily, the 
following four month the number is reduced to two drugs daily. Success rates of 
this combination are more than 85% in Germany.52 
Table 4 Most commonly used tuberculosis protocol in Germany. In the six months treatment 
protocol, a combination of four antibiotic substances is given once daily for the first two months 
followed by four months period of two antibiotic substances, also administered once daily.53  
 Medication 
Daily dose  
[mg/kg 
bodyweight] 
Max. dose/day 
[mg] 
(depending on body 
weight) 
Dosing 
regimen 
Intensive 
phase 
Isoniazid 
 + Rifampicin 
+ Pyrazinamide  
+ Ethambutol 
5 
10 
25 
15 
200/300 
450/600 
1500/2500 
800/1600 
2 months 
1-0-0 
Continuation 
phase 
Isoniazid  
+ Rifampicin 
 
 
4 months 
1-0-0 
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Despite the high response rate in the industrial world it is important to stratify 
patient based on the resistance of the bacterial strain they are carrying, pulmonary 
or extrapulmonary TB, co-infections (e.g. HIV) and other characteristics such as 
pregnancy or alcoholism (as TB drugs are potentially hepatotoxic) to provide best 
care while reducing the chance of side effects. Two examples illustrate the 
importance of patient stratification on individualization of therapy: 
 Multidrug-resistant tuberculosis (MDR-TB), TB resistant to at least 
isoniazid and rifampicin, affects about 480,000 patients worldwide in 
2014.54 These patients must be identified and treated more intense as 
mortality rate in these cases is particularly high. In cases of a diagnosed or 
strongly presumed resistant TB, an individualized approach must be 
sought. Therapy must consider the possibility of cross-resistance and 
should include drugs that are most likely to be effective. Injectable 
treatment is typically necessary. The WHO provides tables that list 
different groups of second-line TB drugs that should be used in 
individualized treatment regimens.53,55  
 A major problem in TB treatment remains the co-infection with HIV. In 
some parts of Africa of all TB infected patients 80 % are also HIV-
positive, while the overall worldwide co-infection percentage is around 
15 %.53 Potential for interaction between TB drugs antiretroviral treatment 
is considered high, especially for rifampicin. Drugs for the patients should 
therefore be selected based on the least possible interaction chance. As 
death rates among HIV-positive TB patients are considerably higher than 
in HIV-negative it is essential that patients receive HIV treatment as well 
as TB therapy.53,56  
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Due to the complex and tedious therapy, it is especially difficult to gain control of 
the disease in developing countries. Agencies like FDA, EMA, the German 
Robert Koch-Institut and organizations such as WHO make a huge effort to 
collaborate and find a common approach to fight this deadly infection. Yet, it is a 
long way to go.  
A little progress in the fight against ever more increasing resistance was made in 
December 2012, when the FDA approved a new drug, Sirturo (bedaquiline), under 
the accelerated approval program for treatment of multidrug-resistant pulmonary 
tuberculosis when other alternatives are not available. Like other TB drugs, 
Sirturo should be used in combination with other TB-fighting drugs.57 Sirturo is 
the first new medicine for TB treatment in almost fifty years.58 On July 25th, 2013, 
the EMA recommended to refuse marketing authorisation for Delamanid, another 
new drug that was supposed to treat MDR-TB. The CHMP initially found “that 
the benefits of Delamanid […] had not been sufficiently shown”59 however, the 
product was approved as an orphan medication soon after.60  
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4.4.2 Helicobacter pylori  
Stomach ulcers and gastritis were generally treated until the end of the 1980s with 
antacids, substances that neutralize or reduce stomach acidity. In 1983, a report in 
“The Lancet” describing “unidentified curved bacilli on gastric epithelium in 
active chronic gastritis” revolutionized the treatment of gastritis and stomach 
ulcers.61 The bacterium was found in patients with chronic gastritis. The authors 
of this article, Barry Marshall and Robin Warren, were awarded the Nobel Prize 
in in Physiology or Medicine 2005 for the discovery of the bacterium that was 
initially named Campylobacter pyloridis and later renamed Helicobacter pylori.62 
The identification of this particular bacterium suggested that ulcers and gastritis 
may underlie different mechanisms of pathogenesis other than gastric 
hyperacidity or stress and further research supported this. Today, it is widely 
accepted that H. pylori is one of the main causes for ulcers and other diseases of 
the upper gastrointestinal tract, including cancer which is why H. pylori was 
classified as a type 1 carcinogen by the WHO in 1994 as it is a risk factor for the 
development of gastric cancer.63 More than half of the global population is 
infected with this organism with a higher prevalence in developing than in 
industrialized countries.64,65 The majority of infected persons, however, will 
remain asymptomatic.66  
The organism cannot survive for a long time in the acidic environment of the 
stomach. Hence, it has evolved a mechanism to avoid the acidic environment to 
colonize the stomach anyway. It does that by using its flagella swimming into 
mucus layer towards the epithelial cells where the pH is higher. In addition, the 
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bacterium generates high amount of urease that produces carbon dioxide and basic 
ammonia, which increases the pH in the surrounding area.67,68  
Invasive and non-invasive methods for H. pylori detection exist. Non-invasive 
procedures are antigen detection in stool or the carbon-urea-breath-test. For the 
breath test, patients are orally given 13C-labelled urea. The high urease activity of 
the bacterium cleaves urea producing ammonia and labelled carbon dioxide that 
can be detected in the breath.64 Once H. pylori is shown to be present the first-line 
therapy for eradication is a triple therapy consisting of a proton pump inhibitor 
(PPI) and two antibiotics. There is a choice of several suitable PPIs, omeprazole 
(20 mg), esomeprazole (20 mg) and pantoprazole (40 mg) are the ones most 
commonly used. In the Italian triple therapy, clarithromycin and metronidazole 
are used as antibiotics; the French therapy metronidazole is replaced by 
amoxicillin.69 In Germany, as already mentioned, a combination pack containing 
pantoprazole (40 mg), amoxicillin (1000 mg) and clarithromycin (500 mg) for a 
seven-day therapy with the brand name ZacPac is approved.19 Quadruple 
therapies use a PPI, metronidazole, tetracycline and a bismuth salt. A bismuth free 
quadruple therapy (concomitant therapy) exists as well; both quadruple therapies 
have demonstrated superiority when compared to standard therapy.69 Current 
research indicates that eradication rates achieved by triple therapy have lost 
efficacy over the years and are now less than 80% due to the development of 
antibiotic resistance primarily to clarithromycin.70 A new approach of combining 
all previously used substances is the sequential therapy. This protocol administers 
the antibiotics not simultaneously but in a sequence and has initially suggested 
higher eradications rates than triple therapy (84.3 %)71 but newer studies indicate 
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non-superiority of the sequential therapy and is no longer recommended in the 
German guideline.69,72  
Table 5 Most commonly used H. pylori first-line eradication protocols in Germany69 
Name Medication Dosing 
Italian triple 
therapy 
PPI + clarithromycin (250-500 mg) + 
metronidazole (400-500 mg) 
7 -14 days 
1-0-1 
French triple 
therapy 
PPI + clarithromycin (500 mg) +  
amoxicillin (1000 mg) 
7 -14 days 
1-0-1 
Quadruple therapy 
PPI +  
bismuth potassium salt (140 mg) 
tetracyclin (125 mg) + metronidazole 
(125 mg) 
10 days 
 
Concomitant 
therapy 
PPI + clarithromycin (500 mg) + 
amoxicillin (1000 mg) + metronidazole 
(400-500 mg) 
7 days 
1-0-1 
 
Thanks to the discovery of H. pylori, patients with ulcer and gastritis now receive 
a differentiated diagnosis for the cause of their medical condition. Based on this 
diagnosis, an individual therapy can be provided which takes into account 
different pathogenesis of peptic ulcer and gastritis.  
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4.4.3 BiDil – the “race drug” 
The product BiDil is an in many respects remarkable example of an attempted 
targeted combination drug. The FDA approved the drug in 2005 for treatment of 
heart failure for patients that “self-identify as black”.73 Interestingly, two active 
substances were combined in this product, which usually play a minor role in the 
treatment of heart failure. It consists of two vasodilators, hydralazine 
hydrochloride and isosorbide dinitrate (ISDN). Both compounds have long been 
available generically. Hydralazine receives only little attention in the German 
guidelines for heart failure.74 The vasodilatory effects of ISDN are mainly used in 
the treatment of angina pectoris. The FDA first rejected BiDil in 1997 since the 
data for the tested population, that included all races, could not show the drug’s 
efficacy convincingly. The company was advised by the FDA to review their data. 
A post hoc subset analyses indicated that the drug works better in black patients, 
while no benefits were observed for white patients. A new clinical trial called A-
HeFT (African-American Heart Failure Trial) with self-identified African-
Americans who suffered from NYHA class III or IV heart failure was 
conducted.75,76 In this study, BiDil succeeded to show efficacy through the 
reduction of deaths by 43 % and a 39 % decrease in hospitalization compared to 
standard of care and was authorised on the basis of these figures by the FDA. 
Approving a drug for a specific race, based on patients’ self-identification, was an 
unprecedented regulatory situation. The FDA declared the approval as “[…] a 
step toward the promise of personalized medicine” and emphasized that the drug 
combination is a treatment from which not all patients benefit but only a few.73 
After being approved, the drug and its intended use were cause for many 
discussions. Especially the self-identification of patients was criticized as a poor 
surrogate for stratification. “Self-identified black” is a purely subjective 
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stratification that is scientifically untenable. It was never discovered why the drug 
seemed to be more effective in black patients. A causal link between a target 
structure and effect was never found and no genetic markers could be identified. It 
has been much debated that race does not automatically corresponds to a certain 
genetic heritage from which the drug’s effect can be derived. Furthermore, the 
pivotal study raised concerns. The study was conducted with black patients only 
without any involvement of other ethnic groups as a control, thus the extent of the 
benefits of black patients against white patients was not determined, said 
critics.76,77,78,79  
The FDA answered to those critical concerns and justified the agency’s decision 
as a reasonable conclusion based on data from clinical studies. They emphasized 
that there had been two well-controlled, randomized trials prior to the pivotal 
study that led to the approval in which black as well as white patients were 
represented. No clinical benefit for the white population was indicated by these 
two studies so that the study design for A-HeFT with exclusively black population 
was considered rational. Confronted with the accusation about the missing 
knowledge why the drug works better in black patients, the FDA argued that this 
is not a legal requirement. It is essential to show that a drug works according to its 
claim but not why it works that way. The lack of knowledge about why the drug is 
more effective in African-Americans is not a sufficient reason to deny a group of 
patients access to a drug from which they clearly benefit. The FDA was also 
astonished that so much criticism arose from the fact that BiDil was approved as a 
race-specific drug. For many years now, it is a requirement to include all sorts of 
different groups in drug testing trials such as patients of different ages, sexes and 
even races since it is commonly known that drugs work differently among patient 
groups. A drug’s effect and metabolism differs for example in man and women or 
elderly patients and younger ones. Therefore, it is not remarkable that a drug 
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shows a better effect in one race compared to another and that this characteristic is 
considered in the approval.80  
Despite all the concerns, the approval of BiDil was of great economic interest for 
the marketing authorisation holder, NitroMed, because the drug’s patent was 
extended by 15 years through the approval as race-specific drug, which would 
have otherwise expired in 2007.77 The economic expectations for the drug were 
initially large, 750,000 patients and annual sales of $825 million were expected,81 
but sales fell significantly short of expectations because sceptical physicians and 
patients did not adapt the drug very well. 
Despite the limited success of the drug, it is an example how products, which have 
already been in the marked for some time, can enter new therapeutic fields by 
identifying subgroups. It may help old medicines gain new economic power and 
relevance in therapy.  
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5 Applications of therapeutic concepts 
Combination of medications can be realized using fixed combinations, 
combinations packs or evidence displayed in medical guidelines. Despite the 
benefits of these alternatives there are several disadvantages connected with that 
as well. These are mainly the missing dosage flexibility in fixed combinations and 
the varying degree in quality and absence of authorisation in medical guidelines. 
Many diseases however require combination therapy such as tuberculosis or 
helicobacter. In other cases combinations seem to be beneficial for defined patient 
groups (see Chapter 4.4). Especially when a disease mechanism is very well 
known and a patient population can be defined in which this pathology is present, 
combinations can serve as a valuable tool in therapy. Therapeutic concepts can 
compensate the disadvantages of other combination alternatives described above 
by having a flexible yet authorised arrangement. 
Therapeutic concepts are rather complex due to the various possibilities of 
combinations and the fact that the products of the combination shall be marketed 
independently, which poses an elevated risk compared to single drug treatment. 
Hence, therapeutic concepts are particularly interesting in distinctive and well-
defined patient groups whose pathologic pathway is well understood to reduce 
unexpected risks. One potential field of application for therapeutic concepts 
would eventually be personalized medicine. This field of research is based greatly 
on genomic approaches and strives to identify the reaction of patient groups 
towards specific treatments. The research in this area is likely to discover new 
cellular pathways and optimized therapies derived from this knowledge. The new 
findings expected in this area can lead to an increased use of combinations with a 
scientific rational to target therapy to multiple cellular pathways thus making it 
superior to single drug treatment. Personalized medicine is therefore particularly 
noteworthy for therapeutic concepts and is therefore presented in further detail in 
the following sections. 
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5.1 Personalized medicine 
Drugs are usually administered based on the experience that it provides a 
sufficiently high probability that it will help the patient in his suffering. However, 
not every drug works equally well in every patient. A drug that helps one patient 
may fail in the next patient. The probability that a certain drug will be effective is 
different for each patient. This is true for almost any drug to varying degrees. 
Studies show that the response rate of patients to a certain pharmacological 
intervention can be extremely low. Response rates in Alzheimer’s therapy for 
example can be as low as 30 %, efficacy rates for depression or schizophrenia 
may reach around 60 %. Even COX-2 analgesics only show efficacy rates of 
80 %.82 Reasons for the response rate are numerous and can include inappropriate 
dosing or lack of compliance in addition to physiological causes. The situation is 
similar for adverse reactions. Not every patient experiences a drug’s adverse 
reactions. If side effects occur, they may have varying severity. It is usually 
impossible to predict which patient benefits from a drug and which will suffer 
from side effects.  
The development of personalized medicine strives to change the predictability of 
these outcomes since several years. It means to increase the likelihood of 
effectiveness and reduce the adverse effects for selected drugs based mainly on 
genetic and biological markers. Currently it is not possibly to determine the 
chances of efficacy for all therapeutic classes, in fact there is only a small 
percentage of therapeutics for which evidence based prediction is now possible. 
The presence of personalized medicine is founded on the growing knowledge 
about cellular signalling pathways, which can be used in drug development. A 
more detailed insight into the cellular pathways and a complete understanding of 
the biochemical response to drugs provides better chances to target drug therapy.15  
In the last decade, personalized medicine has raised great anticipation for the 
medicine of the future and has in fact become a synonym for modern medicine. 
No clear definition for the phrase actually exists and it is interpreted quiet 
differently among various interest groups. The definition of the NIH Talking 
                                                 
82
 Spear BB, Heath-Chiozzi M, Huff J. Clinical application of pharmacogenetics. Trends Mol 
Med. 2001;7(5):201–4. 
5 Applications of therapeutic concepts 
 
 51 
 
Glossary of Genetic Terms however can be regarded as consensus for most 
stakeholders. 
Personalized medicine is an emerging practice of medicine that uses an 
individual's genetic profile to guide decisions made in regard to the 
prevention, diagnosis, and treatment of disease. Knowledge of a patient's 
genetic profile can help doctors select the proper medication or therapy 
and administer it using the proper dose or regimen. Personalized medicine 
is being advanced through data from the Human Genome Project.83  
Personalized medicine strives to deliver the right drug to the right person at the 
right time and at the right dose; tailoring the medicine to the patient is based on 
genetic information. Pharmacogenomics and personalized medicine are often used 
interchangeably.84,85  
Personalized medicine means to identify a patient subgroup that exhibits a certain 
clinical characteristic. Personalized medicine is in fact not a medicine 
personalized for one individual patient. The personalization takes into account 
only personal markers, mostly of genetic origin, but not actual personal 
circumstances. The individual differences of patients with respect to heritage, 
social environment and way of life are not considered, even though these are also 
relevant factors for diagnosis and treatment outcomes. Personalized medicine 
means a purely scientific stratification and not a personalization on an individual 
social basis. It is rather “stratified” than “personalized”. Terms like “targeted 
medicine” or “stratified medicine” that are used as well are more indicative of the 
approach. 
Treatment with a personalized medicine drug often requires testing of a certain 
marker prior to treatment. Which marker test is required depends on the drug that 
is intended to be used and its mechanism of action. Most markers are of genetic 
nature but can concern different aspects of genetics such as: 
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 Variations in metabolism (e.g. cytochrome P450-enzymes) 
Depending on the individual expression of the metabolic (CYP-) enzymes 
substances can be metabolized faster, slower or not at all. Differences in 
metabolic enzymes may influence the effectiveness of drugs in different 
ways. For example, a pro-drug cannot be transferred in adequate quantity 
into the active form when the corresponding enzyme is insufficiently 
available. Furthermore, a too slow degradation of active substance or 
metabolites may cause an accumulation, which in turn could lead to a 
higher risk of adverse effects. 
 Gene mutations 
Mutations in genes can be associated with a higher risk of cancer. Certain 
mutations are target of personalized medicine and the pharmaceutical will 
only be effective when the corresponding mutation is present. 
 Other (non-genetic) biomarkers 
Based on the test result it can be determined whether the patient should receive 
the “personalized medicine” or conventional treatment. Figure 3 shows an 
example of a possible stratification scenario. A larger group of patients with the 
same diagnosis (e.g. lung cancer) undergoes a test to determine molecular 
differences. If, in case of lung cancer, a mutation of the EGRF (epidermal growth 
factor receptor) gene is present the group of patients with the mutation a different 
treatment will be administered than to the group that shows no mutation, thus 
creating two subgroups with one receiving the “personalized treatment” with the 
promise of a higher treatment success. 
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Figure 3 Personalized medicine: A patient cohort is tested for a specific marker in order to 
stratify the group into subgroups. Depending on test results, the groups receive different 
treatment, the one that is most likely for them to be effective.86  
 
The very first articled found on PubMed database concerning personalized 
medicine was published in 1999 by R. Langreth and M. Waldholz in The 
Oncologist called ”The new era of personalized medicine”87. This article was the 
first to discuss the pharmaceutical industry’s efforts towards so-called “niche-
busters” (drugs that are successful in a smaller subpopulation of patients) instead 
of continuing looking for one-size-fits-all blockbuster drugs and the vision of 
tailor-made drugs based on individual genetic makeup. Several big pharma 
companies had started to invest the genetic diversities hoping to find genetic 
markers that would help to determine whether a drug works in a patient or if it is 
likely to cause adverse reactions.  
  
                                                 
86
 Pfizer. What is Personalized Medicine? [Accessed on: 25 Jul 2015]. 
http://www.pfizer.ie/personalized_med.cfm  
87
 Langreth R, Waldholz M. New era of Personalized Medicine. Oncologist. 1999;4(5):426–7. 
5 Applications of therapeutic concepts 
 
54 
Two criteria must at least be met to raise the industry’s interest in developing 
drugs for personalized medicine: 
1. An economically interest market must exist.  
Costs for developing a targeted medicine differ from those of conventional 
drug development. The duration of time and cost consuming clinical trials 
may be shortened through prior patient stratification as the evidence of 
effectiveness can be more easily provided, which leads to faster access to 
market time and longer patent protection time. However, the patient 
population receiving the drug once approved is significantly smaller than 
of a one-size-fits-all. A high therapeutic efficacy compared to alternative 
therapies justifies higher market prices on the other side.88  
2. Identification of the subgroup must be feasible.88 This means that the 
detection of the patient markers must be both technically feasible and the 
expenses are not too high.  
One of the first approved drugs in the area of personalized medicine was 
trastuzumab (trade name: Herceptin) by Genentech, a monoclonal antibody that is 
only to be used when the patient overexpresses the Human Epidermal Growth 
Factor 2 (HER2), a receptor protein which is encoded by the HER2/neu gene. 
Before starting treatment, it is mandatory to examine the patient’s HER2 status in 
the laboratory as the monoclonal antibody only has beneficial effects when the 
receptor is overexpressed.89 It gained approval from the FDA in 1998, the 
European market authorisation was granted in 2000. Since 2010, the product is 
also approved for the treatment of stomach cancer. A test detecting the gene 
amplification for HER2/neu is mandatory before administering the drug to the 
patient. Since the mid-90’s more and more drugs require determination of 
biomarkers before starting treatment (see Table 7) 
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Personalized medicine can be interpreted very differently by the existing fields in 
medicine. There is no definition yet what personalized medicine is about, 
statements on definition range from a purely biomarker-oriented approach in 
disease treatment to the personal needs of an individual patient, which leaves 
much space for interpretation. It can be said that the diseases that personalized 
medicine focusses the most on, according to the number of published articles and 
approved products, are cancer, diabetes, autoimmunity diseases and 
cardiovascular pathologies. Even though the first drugs were approved over ten 
years ago, regulators, industry and the medical sector are still just starting to find a 
good approach on this topic. There are a huge number of working parties on 
pharmacogenomics and personalized medicine by agencies (Pharmacogenomics 
Working Party (PgWP) by CHMP, Interdisciplinary Pharmacogenomics Review 
Group (IPRG) by FDA), universities or industry.  
There is also a huge public interest in this topic, news magazine such as Spiegel 
have featured various detailed articles about hopes and concerns of an 
individualized therapy in the past years.90  
Personalized medicine does not only promise a targeted treatment in case of 
illness but also envisions that diseases can be detected even before their 
manifestation and can then be treated preventively. Genetic data measures for 
individual patients or patient groups, such as families, could be used to react as 
soon as possible with available prevention strategies when a certain marker is 
present. Prevention strategies may include several options, such as medication or 
change of life style. An inherited genetic mutation that indicates a high risk for a 
specific type of cancer may even lead to surgery in order to reduce the risk of this 
cancer, such as for example an oophorectomy in women with proven BRCA1/2 
(BReast CAncer) mutation who have an elevated risk of ovarian cancer.91 In cases 
where no adequate prevention is available, the investigation of the genetic status 
at an early stage can lead to quicker selection of an appropriate therapy with less 
try-and-error approaches.  
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Personalized medicine means not only to determine which is the right medication 
for the patient but can also determine in some cases which is the wrong choice for 
the patient. Biomarkers that predict the patients risk for serious adverse reactions 
exist for several drugs. For example, serious hypersensitivity reactions are a 
feared side effect in the treatment of HIV infections with abacavir. The 
manufacturer of abacavir demonstrated in a clinical trial that this reaction was 
strongly associated with the presence of the HLA-B*5701 (human leukocyte 
antigen-B) allele which had a prevalence of 5.6 % in the patient population. A 
screening for this biomarker prior to abacavir treatment significantly reduced the 
appearance of the hypersensitivity reaction. Prospective screening for the HLA-
B*5701 allele is mandatory to protect these patients from the serious adverse 
effects of the drug.92,93 Other examples for biomarkers that similarly determine a 
patient’s likeliness to response adversely to a drug are listed in Table 7. 
A further goal of personalized medicine is to increase patients’ therapy 
compliance. Compliance describes the degree to which a patient correctly follows 
the therapeutic intervention that a health care professional has prescribed and can 
referred to as adherence. Compliance is influenced by a large amount of factors 
and has a major share in the success of any therapy concluding that non-
compliance on the other hand has a huge part in therapy failures. WHO has 
reported in 2003 that 50 % of patients with chronic diseases are non-compliant.94 
Non-compliance can be affected by a variety of reasons. Onset of adverse reaction 
or the fear of such or absence of the perception of the therapy effect often causes 
non-compliance. Other explanation may include poor understanding of the 
treatment regime and benefit, lack of communication with the physician, costs, 
complicated dosing or multi-medication and comorbidity. Treatment failure and 
hospital admissions due to non-compliance result not only in negative health 
effects but also in high costs. Improving compliance is therefore an important 
issue and personalized medicine might indeed offer an approach in some cases. A 
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biomarker based diagnostic and therapy can increase the participation in health 
care decision for both physicians and patients and support communication and 
compliance as the patients receives a positive feedback regarding safety and 
efficacy of a therapy. By dosage adjustment or not prescribing critical drugs side 
effects can be prevented, this increases the compliance.95,96  
In conclusion, the goal of personalized medicine is to improve quality of life by 
means of better choices of therapy and less adverse reactions as well as to 
improve the cost-effectiveness of therapy by faster choosing of a therapy and by 
improving patients’ understanding and compliance of those therapies.  
However, personalized medicine has still several obstacles to overcome. Some 
major challenges are not yet addressed. Today, there is no sufficient evidence, that 
personalized medicine is superior in the long term than the standard of care. The 
identification of relevant genetics is rather slow. Even if a genetic variant is 
identified, its clinical significance on risk prediction or treatment success is 
questionable.97 Comparative warfarin sensitivity trials, for example, showed little 
benefit of the sensitivity test over careful patient monitoring.98 For mutations that 
are associated with an elevated risk of cardiovascular diseases in women, a study 
showed that the predictive power of the mutation presence of chromosome 9p21.3 
does not give additional information on the risk.97,99 There is also a high demand 
for evidence of promised cost-effectiveness of personalized medicine. Only by 
providing evidence, payers will agree to invest in personalized medicine therapies. 
The economic evaluation of genome-based therapy presents itself as very 
complex, as many different factors contribute to it and long term cost savings are 
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difficult to determine.100 Essentially, cost-effectiveness needs to be determined for 
each condition and each therapy individually. Even for personalized medicine, 
therapies that are applied often, the evidence for cost-effectiveness is still not 
complete. For example, trastuzumab is found to be cost-effective only under 
certain circumstances (HER2-positive patients under 65 years of age).101 No 
overall cost-effectiveness evidence for genome-based therapies is yet available.  
Personalized medicine in summary offers various opportunities for modern 
medicine. Due to the complex nature of personalized medicine several obstacle 
are however yet to overcome before all the promises can be implemented 
practically. While some genetic based diagnostics and treatment have already 
proven their value to health care, others remain uncertain. Personalized medicine 
remains a heterogeneous research area, which, like conventional medicine, will 
result in successful medical treatment options as well as in those that will fail to 
meet the demands.  
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Table 6 Summary of aims and challenges of personalized medicine 
Goals and Visions vs. Problems and Challenges 
Prevention rather than reaction 
 Lacking evidence for superiority 
to SOC 
Less try-and-error, faster choice 
of best therapy 
 Proper biomarker identification 
must be available 
Less ADRs 
 Lacking evidence for cost-
effectiveness 
Improving compliance  Possible genetic discrimination 
Better cost-effectiveness  Disregarding social environment 
Improving Quality of life 
 Shift of priorities: Less 
conventional treatment and 
research? 
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5.1.1 Biomarkers 
In the concept of personalized medicine biomarkers play an essential role. It has 
already been described that the presence or absence of a certain patient’s 
characteristic is crucial for the effectiveness of specific medicines. Measurable 
indicators of those characteristics are called biomarkers. A genomic biomarker is 
defined by the ICH as  
“[…] a measurable DNA and/or RNA characteristic that is an indicator of 
normal biologic processes, pathogenic processes, and/or response to 
therapeutic or other interventions.”102  
Examples of those characteristics are measurement of gene expression or function, 
single nucleotide polymorphisms (SNPs) in DNA or RNA splicing variations. The 
FDA does not only see genetic information as biomarkers but also all sorts of 
other  
“[...] characteristic[s] that is objectively measured and evaluated as an 
indicator of normal biologic processes, pathogenic processes, or 
biological responses to a therapeutic intervention. A biomarker can be a 
physiologic, pathologic, or anatomic characteristic or measurement that is 
thought to relate to some aspect of normal or abnormal biologic function 
or process. Biomarkers measured in patients prior to treatment may be 
used to select patients for inclusion in a clinical trial. Changes in 
biomarkers following treatment may predict or identify safety problems 
related to a drug candidate or reveal a pharmacological activity expected 
to predict an eventual benefit from treatment.”103  
Biomarkers, that are assumed to improve therapy or predict an outcome, are found 
every day but it is vital to find those that will actually proof significant in clinical 
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use. The regulatory system needs to meet the requirements to ensure a safe and 
effective medical treatment.  
The EMA recommends involving biomarkers very early in clinical research and 
trials to judge the biomarker's influence on prediction and treatment (ICH topics 
E15 and E16). Retrospective studies can be challenging since they lack the power 
of well-planned prospective trials. Nevertheless, even retrospective analysis can 
save a drug that otherwise would probably struggle to get an approval. An 
example for such a scenario is the product BiDil. As already discussed, the 
product was rejected by the FDA at first, but later analysis revealed that the 
combination had a statistically better effect in Afro-Americans than in Caucasians 
and so the FDA approved it for that purpose. Thus, a very easy to find 
“biomarker” helped placing a drug on the market for some patients’ benefit 
(compare Chapter 4.4.3). 
 
Figure 4 Use of biomarkers in clinical trials 1970-2011.104  
Diagnostics, especially in-vitro diagnostics (IVD), in context of personalized 
medicine are not very much in focus, at least in the European Union. The FDA 
has worked out an approach to deal with drug/diagnostic combinations. If an IVD 
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is needed for the safe and effective use of a drug, the specific companion 
diagnostic needs to undergo clinical trials and FDA approval, otherwise the drug 
will not receive market authorisation. In the European regulatory framework, 
IVDs are subject to the IVD directive 98/79/EC. Since most of the IVD that are 
needed for personalized medicine drugs do not belong to List A or B in Annex II 
the conformity assessment procedures lays in the responsibility of the 
manufacturer. This bears a high risk, because no independent third party (Notified 
Body) is involved. To minimize risks due to weak performances of IVDs, the 
European Union should raise the standards and requirements for IVD. A first 
improvement could be the evaluation of the test by a reference laboratory or 
stricter phrasing in the SmPC on how tests, for example when looking for an 
overexpressed receptor, should be performed, and more information about how 
they were done in the clinical trials. The diagnostics issue is surely one that the 
EC and the EMA will have to work on in order to increase the value of 
personalized medicine.  
5 Applications of therapeutic concepts 
 
 63 
 
5.1.2 Personalized medicine drugs  
The drugs approved for personalized medicine are often based on mandatory or 
recommended testing for certain genetic markers (“Biomarkers”). The outcome of 
the test determines whether the drug in question will be effective for the patient or 
will show if the patient has a high risk for a serious adverse reaction. Table 7 
gives an overview on some of the most prominent examples for personalized 
treatments approved in Germany and Europe. Most of the medicinal products are 
used in oncology. The table shows that personalized medicine is in great need of 
validated diagnostic tools that help to determine if the listed medications are 
beneficial for the patient in the specific situation. If the diagnostic give a false 
positive or false negative result the patient may be treated with an ineffective 
product. A correct test result is therefore indispensable. As a test exists for most 
drugs that are considered personalized medicine, therapeutic concepts provide an 
opportunity to include the corresponding diagnostic in an authorised treatment 
combination.  
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Table 7 Selected drugs approved for personalized medicine in Germany and biomarkers 
associated with effectiveness or adverse reaction of the drug. Test are conducted to determine 
either the effectiveness of the medication or a patient’s likeliness to suffer from severe adverse 
effects.105  
Active 
ingredient 
Indication 
Test mandatory 
or 
recommended  
Subject of 
test/Outcome 
Test result 
indicates 
Abacavir HIV/Aids Mandatory 
Presence of HLA-
B*5701 allele, which 
is strongly associated 
with hypersensitivity 
reactions, only to be 
used in HLA-B*5701 
negative patients. 
Adverse drug 
reaction 
Arsenic trioxide 
Oncology/ 
APML 
Mandatory 
Presence of 
PML/RAR alpha 
gene, only to be used 
in patients with 
positive test result 
Effectiveness 
Azathioprine 
Immuno-
suppressant 
Recommended 
Absence or low 
activity of the enzyme 
TPMT causes higher 
risk for bone marrow 
suppression 
Adverse drug 
reaction 
Carbamazepine Epilepsy Recommended 
Presence of HLA-
B*1502 allele, which 
is associated with fatal 
skin reactions, only to 
be used in HLA-
B*1502 negative 
patients 
Adverse drug 
reaction 
Cetuximab 
Oncology/ 
Colorectal 
cancer 
Mandatory 
Presence of wildtype 
KRAS gene, only to 
be used in patients 
carrying the wildtype 
Effectiveness 
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Active 
ingredient 
Indication 
Test mandatory 
or 
recommended  
Subject of 
test/Outcome 
Test result 
indicates 
Crozotinib 
Oncology/ALK 
(NSCLC) 
Mandatory 
Presence of ALK 
gene, only to be used 
in patients with 
positive test result 
Effectiveness 
Erlotinib 
Oncology/Lung 
cancer 
Mandatory  
(since 08/11) 
Presence of EGFR 
mutation/overexpressi
on, only to be used in 
patients with positive 
test result 
Effectiveness 
Fulvestrant 
Oncology/breast 
cancer 
Mandatory 
Presence of hormone 
receptor-positive 
breast cancer cells, 
only to be used in 
positive tested patients 
Effectiveness 
Imatinib 
Oncology/AML 
and CML 
Mandatory 
Presence of 
Philadelphia 
chromosome, only to 
be used in positive 
patients 
Effectiveness 
Ivacaftor Cystic fibrosis Mandatory 
Presence of G551D 
mutation in CFTR 
gene, only to be used 
in patients with 
positive test result 
Effectiveness 
Lomitapid 
Homozygous 
familial hyper-
cholesterolemia 
Recommended 
Genetic evidence of 
homozygous familial 
hypercholesterolemia 
Effectiveness 
Maraviroc HIV/Aids Mandatory 
Presence of CCR5 
receptor (HIV 
tropism), only to be 
used in patients with 
positive test result 
Effectiveness 
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Active 
ingredient 
Indication 
Test mandatory 
or 
recommended  
Subject of 
test/Outcome 
Test result 
indicates 
Natalizumab 
Multiple 
sclerosis 
Recommended 
(since 06/11) 
Test for Anti-JCV 
antibodies, JCV may 
cause progressive 
multifocal 
leukoencephalopathy 
Adverse drug 
reaction 
Tamoxifen 
Oncology/breast 
cancer 
Recommended 
a) Presence of 
hormone receptor-
positive breast cancer 
cells, only to be used 
in positive tested 
patients 
b) Test for expression 
ratio of HOXB13, 
IL17BR genes to 
determine recurrence 
risk of cancer, based 
on results mono or 
combination therapy 
Effectiveness 
Trastuzumab 
Oncology/breast 
and stomach 
cancer 
Mandatory 
Presence of HER2 
overexpressing 
tumour, only to be 
used in patients with 
positive test result 
Effectiveness 
Vemurafenib 
Oncology/ 
melanoma 
Mandatory  
(since 02/12) 
Presence of BRAF-
V600 mutation, only 
to be used in patients 
with positive test 
results 
Effectiveness 
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The complete list of drugs that are considered personalized medicine contains 47 
approved substances in Germany to date (February 2016). Of the 47 substances, 
36 are used in oncologic therapies, which corresponds to 77 % of these drugs. 
A test to either check for the products effectiveness or an adverse reaction is 
mandatory for 39 medications (83%). This data show how important diagnostic 
test are for a safe and effective use. Therefore is must be ensured that the 
diagnostic actually gives correct results. 
5.1.3 Development of personalized medicine  
The idea of tailoring the right medicine to the right patient at the right time is as 
old as medicine itself. In a time where people had no understanding for basic 
human physiology, let alone DNA, doctors already tried to find the best cure for 
their patients. One of the most well-known physicians of ancient time was 
Hippocrates (c. 460 BC – c. 370 BC). He understood that he was not treating 
conditions but an individual person suffering from this condition. Today, the 
often-quoted statement, “It is more important to know what sort of person has a 
disease than to know what sort of disease the person has”106 by Hippocrates is one 
of the highest credos in personalized medicine. However, it was not until 1866 
before the first scientific proof about a person’s individual characterization was 
postulated by Gregor Mendel.107 His experiments with pea plants and their 
hybrids led to Mendel’s Laws of Inheritance and made him “the father of modern 
genetics”.108 Another turning point in understanding biological differences 
between individuals was the discovery of blood types and the characterization 
with the ABO system described by Karl Landsteiner (1868-1943) in 1901.109 This 
finding showed for the first time very undoubtedly that there is no such thing as a 
“one-fits-all” medicine; receiving blood from a person with the wrong blood type 
had mostly disastrous results, which made Landsteiner’s discovery a lifesaver for 
many patients. Only a few years later, Sir Archibal Garrod reports about an 
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“inborn error in metabolism”: alkaptonuria.110 This disease can be diagnosed by a 
person’s urine, which, after exposure to air, turns dark. Later in life, patients 
suffer from arthritis caused by accumulation of homogentisic acid in the tissue. 
Garrod studied several families and found alkaptonuria to be of autosomal 
recessive inheritance, thus linking genetic inheritance and susceptibility to a 
certain disease.111 The demonstrated examples were all important milestones in 
the formation of personalized medicine. However, one of the most important 
discoveries was yet to come, the molecular model of a base-paired DNA 
presented by Watson and Crick in 1953.112 DNA and genetics gained a high 
amount of interest in the scientific world. Researchers focused more and more on 
this field and therefore developed a great variety of tools and technology to 
investigate. In the late 1950’s, different findings suggested a relation between 
genetics and drug reactions. Werner Kalow and a colleague found patients with an 
uncommon susceptibility to the muscle relaxant suxamethonium resulting in 
prolonged apnoea. They had not only the patients’ blood, but also that of their 
family members’ and other test persons analysed. In 1956, he published the results 
proposing the idea that there must be at least two different types of human serum-
cholinesterase.113 Another adverse drug reaction (ADR) was bringing more 
attention to drug – genetics interactions. Primaquine is an agent that has been used 
to treat malaria since the 1940’s. One side effect was intravascular haemolysis in 
some patients, which can be fatal.114 It was later shown that this was due to a 
glucose-6-phosphate dehydrogenase deficiency.115 Both events draw attention to 
the fact that genetics can affect drug metabolism, and raised the question what 
other adverse drug reactions were possibly caused by related genetic mechanisms. 
The concept of the field of pharmacokinetics was basically established, but it took 
a few more years until the actual term for the genetically caused reactions to drugs 
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came up. Friedrich Vogel was the first to use the word pharmacogenetics in 
1959.116 Today, pharmacogenetics refers to many different aspects of genetic 
differences in metabolic pathways. That includes ADRs caused by drugs, a 
therapeutic effect that can only be achieved in patients with a specific gene 
variation, as well as the testing for genetically caused diseases or for both drug 
safety and efficacy. In the 1960’s the cytochrome P450 (CYP) family was 
discovered, and was soon found to be of great importance for drug metabolism 
and occasionally also for activation of prodrugs. Cytochrome P450 are a large 
group of monooxygenases that plays a very important role in the metabolism and 
therefore in the biotransformation of drugs. Cytochrome P450 enzymes occur in 
all life forms. In humans, the highest concentration of these proteins is found in 
the liver. Polymorphism in the CYP enzymes may lead to either a reduced or 
increased metabolism of a substance, which results either in too little or too high 
concentrations of a drug, causing side effects or failure of therapy.117 Learning 
about the impact on drug therapy due to genetic differences between individuals 
was an important step towards a better and safer health care. However, in the time 
of the discoveries mentioned above having a person tested for their genetic 
variation was almost impossible and very costly. In 1990, the US National 
Institutes of Health (NIH) and international partners, aiming to fully sequence the 
human DNA and help researchers to understand more about genes, founded the 
Human Genome Project and in 2003, it was announced that the full DNA 
sequence was available. The location of all of the approximately 20,500 genes can 
now be identified.118 Having all those information and a completely new set of 
tools to investigate patients’ genome was a huge step also in medical practice. It 
did not take long for the first “personalized” agent to come into the market, in 
fact, even before the Human Genome Project ended. Trastuzumab (Herceptin) 
gained marketing authorisation in the United States in 1998. Just months after 
trastuzumab launching an article in The Wall Street Journal appeared, reporting 
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about a new approach of the pharmaceutical industry, trying to tailor drugs to 
patients based on their genetics; the term “personalized medicine” was coined in 
this very article. The industry’s hope to develop safer and more potent drugs using 
gene research is portrayed.87 Today, research moves faster with every day, the 
information that was obtained results in more and more biomarkers for prevention 
and therapy, new technology, and deeper insights into drug - gene interaction. The 
challenge is to use the mass of information in a way that health care truly profits 
from new discoveries. 
5.1.4 Ethical considerations 
The concept of personalized medicine does not only bring new problems to the 
regulatory framework but also poses a challenge in many different aspects. 
Despite scientific and economics aspects, ethical criteria must be considered. 
There is always criticism that personalized medicine raises more hopes that it can 
fulfil.119 The phrase “personalized medicine” creates a misleading image for 
patients, who expect a person-centred care rather than the very scientific genome-
based approach. Biomarkers pop up everywhere and are described for almost all 
common diseases. The problem is that the majority of them are not of great value 
for therapy. Each biomarkers creates a hope of altering the way medicine can cope 
with a certain condition, but this is only true for very few of them. After all this 
research, “there are (only) around 50 drugs that actually have genetic tests as 
part of their labelling” said former FDA Commissioner Hamburg.120 This 
illustrates one of the ethical problems that come along with personalized 
medicine. The question remains whether all the investments, work and research 
put into this part of medicine pay off. It might very well be that only very few 
patients profit from this research while a great number of people suffering from 
common diseases, e.g. high blood pressure, where genetic research is unlikely to 
improve a therapy or prediction, will not benefit. Some people remark that putting 
too much effort into personalized medicine will disregard research on basic care 
of widespread diseases so that in the end despite all the efforts we will come to a 
negative outcome for society. 
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With more and more “personalized” treatment, the amount of genetic data 
available on a person will increase ever more. As the exact handling of this 
information is relatively unclear, the possibility of genetic discrimination based on 
available genetic data exists. People with a high possibility of developing certain 
diseases may be discriminated in health insurance or in employment decisions.  
Personalized medicine is continuously criticized for using the term personalized 
without being truly personalized. The type of treatment is based on a person’s 
genetic but not on the person’s personal environment. Socioeconomic factors such 
as access to education, lifestyle or income are not taken into account but only 
scientific aspects.121 Higher education, income and social status are generally 
associated with better health. Access to clean water, air and safe housing and 
work places also influence health. Individual behaviours like smoking, physical 
activities and diet also contribute to the individual’s health status.122,123 These 
truly personal factors may have a significant impact on the individual disease 
development and treatment outcome, in some cases even more than genetic 
factors.  
Another huge ethical issue is very rarely discussed. Biomarkers and diagnostics 
promise to pick the right patient at the right time for the right therapy. One can 
easily see that this cannot be true for all patients. There will never be a guaranty 
that test, biomarker and laboratory work one hundred percent accurate every time, 
thus producing false negative or false positive results. On the one hand, there will 
be those patients that are chosen for a therapy who will not benefit even though a 
test predicted that they would. Those patients will probably suffer from side 
effects but not profit from the therapy. On the other hand, there will be those 
patients who receive a wrong negative outcome of the test. They are refused 
therapy since they seem unlikely to respond. Health care providers will not want 
to waste time and money on such a patient with the costly biomarker based 
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therapy but instead use an alternative treatment, one that in reality is the one less 
likely to be of use for the patient. With a rising number of decisions based on tests 
and biomarkers, the number of patients that are refused therapy based on this 
“evidence” will go up as well. These considerations should not be left out when 
discussing the vicissitudes of personalized medicine. 
5.1.5 Pharmacovigilance 
Pharmacovigilance, the on-going and systematic monitoring of the safety of a 
medicinal product in order to discover its adverse effects, to assess and understand 
risks and take appropriate action to minimize those risks, is an important and 
compulsory aspect of a drugs life cycle. Personalized medicine promises a safer 
therapy by excluding patients with a high risk of adverse events. The ability to 
identify the right patient subgroup should therefore be in the focus of safety 
assessments. Special attention should be paid to pharmacovigilance in 
personalized medicine, as it is associated with additional risks compared to 
common medicines. These additional risks include the misuse of personalized 
medicine products for “wrong” patients, meaning those patients who should not 
receive the drug because they do not fit the inclusion criteria. In common “one-
size-fits-all” drugs, this risk is practically not present. The misuse might lead to 
serious adverse events or even death. Administering therapy to the wrong patients 
could derive either from a false positive results of a test or because no test was 
conducted due to ignorance about the necessity of the test or limited resources. 
The impact of false positive test results and the resulting unintentional misuse 
should be carefully evaluated in the general risk-benefit analysis. A high number 
of treatments of false positive patients who experience serious adverse events can 
indicate that the corresponding test is not accurate enough. In order to understand 
the necessity of certain test a high education level concerning genetics and 
pharmacogenomics is required. The lack of appropriate resources applies 
especially to developing countries where it is not feasible to conduct complicated 
or costly exclusion testing.124 Therefore, in developing countries special 
precautions and vigilance plans should be maintained.  
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Pharmacovigilance cannot only be used to assess adverse events but can also be a 
tool to identify new beneficial aspects of a drug, resulting in development of new 
therapies, expanded indications125 or a better-defined patient population. 
Investigating underlying mechanism of action and growing understanding of 
genomics can thus be an important part of personalized medicine 
pharmacovigilance. 
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5.2 Orphan drugs: a regulatory challenge for personalized medicine? 
5.2.1 Orphan drug regulations 
Orphan diseases, or rare diseases, are diseases that affect only a small minority of 
patients, which means by definition no more than 5 out of 10,000 in the European 
Union; prevalence in other parts of the world is not considered. Patients often 
have a high level of suffering, as it can take years to get a diagnosis. 
Approximately 80 % of rare diseases are of genetic origin.126,127 Many of these 
rare diseases affect only an extremely small number of patients, while other rare 
diseases, such as cystic fibrosis, affect a much larger group of patients. More than 
55 million people suffer from an orphan disease in Europe and the US.128  
The first initiative concerning orphan diseases was the Orphan Drug Act (ODA) 
that was passed in 1983 in the United States to provide better health care to those 
who suffer from rare illnesses. The FDA defines a rare or orphan disease as a 
condition, which affects less than 200,000 patients in the US, which is a slightly 
different definition than the European. Research for the approximately 6,000 – 
8,000 rare diseases126 is costly and due to the limited number of patients unlikely 
to be profitable. Efforts of pharmaceutical companies therefore were little prior to 
1983, only 10 drugs have been placed onto the market in the decade before the 
ODA. The ODA proposes economic incentives to increase the industry’s 
willingness for developing drugs for rare diseases. Incentives in the US include 
seven years of market exclusivity, fee exemptions from FDA fees, free FDA 
scientific advice and tax credits. The impact of the Orphan Drug Act seems 
remarkable: From 1983 until today, the FDA Office of Orphan Products 
Development (OOPD) has designated more than 2,000 compounds as orphan drug 
and more than 400 of those have been approved.129,130,131 Other countries followed 
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implementing an orphan drug regulation to their legislation; Japan in 1993, the 
European Union in 2000. Similar to the FDA Office of Orphan Products 
Development a European equivalent responsible for orphan drug designation 
within the EMA exists, the Committee for Orphan Medicinal Products (COMP). 
The COMP is composed of one member from each Member State, three patients’ 
organizations representatives nominated by the European Commission, three 
members nominated by the European Commission on the recommendation of the 
EMA, non-voting members from Iceland, Norway and Liechtenstein, one EC 
representative and general observers. Designation in the EU includes 10 years of 
market exclusivity and reduction of agency fees. The regulation led to an 
increased number of drugs for rare diseases, to date there are more than 70 
approved orphan drugs in the Community.128,130,132  
The following criteria must be met in order to gain orphan drug designation 
according to Article 3 of Regulation (EC) No 141/2000 on orphan medicinal 
products: 
 Condition is life-threatening/ seriously debilitating/ serious and chronic 
and 
 Affects no more than 5 in 10,000 persons in the Community or no 
sufficient return without incentives and 
 No approved satisfactory method of treatment or of significant benefit for 
affected persons 
„1. A medicinal product shall be designated as an orphan medicinal 
product if its sponsor can establish: 
(a) that it is intended for the diagnosis, prevention or treatment of a life-
threatening or chronically debilitating condition affecting not more than 
five in 10 thousand persons in the Community when the application is 
made, or that it is intended for the diagnosis, prevention or treatment of a 
life-threatening, seriously debilitating or serious and chronic condition in 
the Community and that without incentives it is unlikely that the marketing 
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of the medicinal product in the Community would generate sufficient 
return to justify the necessary investment;  
and 
(b) that there exists no satisfactory method of diagnosis, prevention or 
treatment of the condition in question that has been authorised in the 
Community or, if such method exists, that the medicinal product will be of 
significant benefit to those affected by that condition.”133  
 
In the US legislation, a medicinal product is qualified for orphan drug designation 
by the limited number of patients and profitability while the European legislation 
additionally considers the unmet medical need as defined in Article 3 (b) of a 
product, which is the main difference between US and EU designation criteria.130 
The US also only grants seven years of market exclusivity. 
Market exclusivity (Article 8 of Regulation (EC) No 141/2000) is an important 
part of an approved orphan drug. However, it does not create a monopoly in its 
indication. According to the regulation, other products that are not similar to the 
first in terms of chemical structure or mechanism of action can be granted orphan 
drug status in the same indication. Likewise, a drug similar to the already 
authorised orphan drug can be approved when it is superior to the first one, 
providing a better safety profile or is more effective. Other derogations are the 
marketing authorisation holders consent to a second applicant (Article 8, 
paragraph 3 a) and lack of supply (paragraph 3 b). In addition, the market 
exclusivity may be reduced to 6 years, should the product be sufficiently 
profitable that maintaining exclusivity is not justified (paragraph 2). 
Drugs can be designated as orphan drug at any stage of development. While the 
decision about orphan drug designation is based on the review and 
recommendation of the COMP, the approval of the drug is processed by the 
CHMP. Orphan drugs are to be authorised by the centralised procedure according 
to Regulation (EC) No 726/2004. The same rules for marketing authorisation 
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applications apply for orphan drugs as for any other drug.134 That means clinical 
trials are necessary to prove the drug’s safety and efficacy. For the majority of 
approved orphan drugs it is feasible to perform full clinical studies despite the 
small number of patients. Therefore, most orphan drugs are authorised on normal 
routes, marketing authorisation “under exceptional circumstances” or “conditional 
approval” is rather rare (compare Chapter 3.3.5).12,128  
 
Figure 5 Proportion of orphan drugs approved in the European Union in different therapeutic 
indications as of 2008 (based on the ICD-10 system for classifying diseases).135  
 
Figure 5 shows the share of orphan medicines in various indications. Most orphan 
drugs that have been approved and marketed in the EU are used to treat rare types 
of cancer. Their share in the market is almost 40 %. The reason for this is partly 
the high unmet medical need; on the other hand, a greater knowledge usually 
exists for rare cancers in contrast to many other rare diseases and the biological 
and molecular differentiation methods improve rather rapidly.135 Drugs for 
metabolic diseases are also present in a high extent.  
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5.2.2 Personalized medicine – from blockbuster to niche-buster to orphan? 
On first glance, it looks as if orphan drugs and personalized medicine do not have 
much in common with each other. The major difference between drugs for 
personalized medicine and those for orphan diseases is the scientific knowledge 
and the economic interest. In personalized medicine, sub-groups of well-studied 
conditions are treated. The pathogenesis of those diseases is usually well 
understood. In contrast, orphan diseases are mostly at a much lower level of 
expertise and medical knowledge. Due to the high heterogeneity and great 
research effort, these diseases gain little economic interest.130 
Today, the majority of drugs that are used are developed to fit as many patients as 
possible. This can be referred to as a “one-size-fits-all” approach, which allows 
the pharmaceutical industry to reach as many patients as possible. Sales of drugs 
like that can exceed the one billion dollar mark per year on a global level; those 
are so-called “blockbuster drugs”. Although these drugs are prescribed to millions 
of patients, not all patients benefit from them. Depending on the indication and 
drug, it is estimated that the overall effectiveness is often below 80 %, but in some 
cases the response rate is even lower. A study from 2001 analysed major drugs for 
important diseases and their efficacy. It was shown for example that selective 
serotonin re-uptake inhibitors (SSRI) antidepressants have an average response 
rate of 62 %, which means that 38 % of all patients do not benefit from therapy. 
For some cancer drugs efficacy seems to be as low as 25 %, leaving 75 % of 
patients that do not respond to therapy. The highest efficacy rate found in this 
study was 80 % for COX-2 inhibitors.82 
One can imagine that future research, driven by the current high interest in 
personalized medicine and the ever-increasing knowledge about molecular 
pathways, will reveal more about a diseases’ mechanism and the role of genes. In 
certain cases, this might lead to “sub-conditions” or more patient sub-populations 
that eventually become a fully acknowledged condition of their own. Knowing 
more about the molecular mechanism of these sub-conditions, it will be possible 
to create drugs that are targeted for this particular mechanism. In consequence, 
this also means that the one-size-fits-all approach will no longer work in many 
cases, as the target population that receives this drug will be smaller than before. 
However, it also means that the response rate to the therapy is likely to be higher 
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than in conventional therapy, as only a selected population receives this therapy. 
Some of the drugs that were developed for a specific sub-population have evolved 
into so-called “niche-busters” in analogy to blockbuster drugs, whose annual 
revenue is similarly high. An example is imatinib, an anticancer agent that is 
marketed in Europe under the trade name Glivec. Imatinib, an inhibitor of tyrosine 
kinase Bcr-Abl was initially approved as a therapy for chronic myelogenous 
leukaemia (CML). Reciprocal translocation between the Abelson (Abl) tyrosine 
kinase gene at chromosome 9 and the breakpoint cluster region (Bcr) gene 
at chromosome 22 leads to the Philadelphia chromosome. The resulting Bcr-Abl 
tyrosine kinase is constitutively elevated. Imatinib decreases the protein’s activity 
by inhibiting ATP binding to the kinase.136,137 With only 55,000 patients, 
imatinib’s 2006 revenue was more than $2 billion.88 This impressive number 
shows how high efficacy of a drug justifies a higher price and makes it 
economically interesting. Medicine for orphan diseases can also achieve 
commercial success. Cerezyme (imiglucerase) is used for the treatment of 
Gaucher disease, the most common of the lysosomal storage disease that is caused 
by a deficiency of β-glucocerebrosidase. This lysosome-localized enzyme cleaves 
glucosylceramide into glucose and ceramide. With the reduced activity of 
β-glucocerebrosidase, glucosylceramide accumulate primarily in macrophages. 
Manifestation of Gaucher disease includes in most cases enlarged spleen and liver 
and patients may suffer from thrombocytopenia and painful skeletal disorders. 
Gaucher disease is considered an orphan disease yet Cerezyme is not a designated 
orphan drug due to the fact that it was authorised in Europe in 1997 prior to the 
orphan drug regulation.138 In 2009 with fewer than 6,000 patients, the annual 
revenue was almost at $1.8 billion.139 These examples show how even therapy for 
small patient populations can achieve high revenues which is especially true if the 
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disease is severe and the treatment is the only one available or very effective. 
These criteria justify a high price and a greater chance of reimbursement that 
increased the industry’s interest in some niche and orphan indication.  
 
Figure 6 Visualization of the general distribution of orphan drugs, niche-busters and blockbusters 
with regard to their sales volume and patient number. 
 
The question is whether the prospect of launching an economically successful 
niche or orphan drug brings major changes to the regulatory system. Will there be 
more drug approvals of orphan drugs and less one-size-fits-all blockbuster drugs? 
Currently a lot of discussion is going on whether there will be a shift from 
blockbuster to so-called niche-buster drugs that are specified for a smaller, more 
defined group of patients,140,141 that would possibly also effect therapeutic 
concepts, when they have been identified for a smaller patient subset. It can be 
envisioned that this development will even go further and create more conditions 
that only a handful of patients suffer from, leading to more orphan diseases and a 
higher amount of requests for orphan drug designation. However, the “condition” 
for which an orphan drug is intended to be used must be a well-recognized 
disease. It is not possible to simply down-slice indications depending on the 
severity and course of a disease or its intensity variants. These are not sufficient 
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features to gain orphan drug designation. Characteristics of a condition for which 
orphan drug resignation is sought must clearly differ from other similar conditions 
and their treatment.135 Personalized medicine might be able, however, to identify 
diseases in which specific, targeted therapies are more successful than earlier, 
especially in the field of oncology where research is most intense. If the 
prevalence of that condition is rare enough in the European Community chances 
are that the industry can benefit from orphan incentives and the number of orphan 
drug designations will rise. The question is, whether this would be a threat to the 
regulatory and health care systems or a chance to improve medical care since 
financial barriers for research are reduced and if such a development is within the 
intention of the orphan drug regulation. 
To answer these questions, it might be helpful to look at other approved orphan 
products that are controversially discussed, namely those products that have an 
orphan designation, but whose active ingredient has already been known before. 
The blockbuster drug sildenafil (Viagra, Pfizer) additionally holds an orphan drug 
designation for the rare disease pulmonary arterial hypertension and is marketed 
under the trade name Revatio since 2005. The well-known compound ibuprofen is 
a designated orphan drug approved in 2004 for the treatment of neonatal patent 
ductus arteriosus (Pedea). Both compounds were already known prior to their 
orphan drug designation and commonly used in other indications; sildenafil for 
erectile dysfunction, ibuprofen is mainly used for pain relief, fever reduction and 
as an anti-inflammatory agent. Even before Revatio was approved, the compound 
sildenafil was already used off-label to treat pulmonary hypertension;142 ibuprofen 
as well was already in use for treatment of neonatal patent ductus arteriosus.143 
Although it is questionable whether such an approach corresponds to the intention 
of the orphan drug regulation, such a development can certainly bring positive 
achievements. On first sight, authorising compounds that are already in use 
additionally as an orphan drug seems like a gift to industry that benefits from 
orphan incentives and possibly higher prices for the orphan drug than the off-label 
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used product with only little research effort.144 On the other hand, orphan research 
can profit from research on blockbuster and other existing drugs. If, for example, 
Viagra had not been approved, its therapeutic benefit in pulmonary hypertension 
may have never been found or even if it was found further investigation and 
research may not have been carried out, as it would not have been profitable. 
Many references concerning safety and efficacy issues had already been available 
due to off-label prescription.142 This could be helpful in the planning of clinical 
trials for the orphan indication, and could speed up the approval process, which 
would make the drug faster available to patients. In this way, the research for 
orphan diseases can benefit from the experience and knowledge of more common 
diseases. The same applies vice versa: study of homozygous familial 
hypercholesterolemia led to the development of statins.145 Findings of 
personalized medicine research can also be beneficial for orphan cancers or other 
rare diseases. If new patient sub-populations can be identified who will profit 
from a new and targeted therapy with better response, this is definitely within the 
meaning of the orphan regulation. Of course, there is always the risk that the 
attractive incentives for orphan products are utilized, for example, by obtaining 
more orphan indications for the same product or developing non-orphan drugs.146 
However, at present, the risk of exploitation seems rather low. The number of 
orphan drugs approval the past years in Europe is illustrated in Figure 7, in. So 
far, 2014 was the year with the most orphan drug authorisations, to be precise 15 
new approvals.132 
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Figure 7 Number of approved orphan drugs in Europe by year of marketing authorization.132  
It remains to be seen if the placement of orphan drugs onto the market will 
actually rise in the future due to new findings in personalized medicine or whether 
the proportion of lucrative drugs for rare cancers increases. At the end, patient 
care should be the highest principle of this regulation. As long as the situation of 
patients affected by rare diseases improves by stimulating orphan research, the 
regulation can be considered successful. Nevertheless, the regulation should also 
be critically examined again in the future to be able to make any improvements if 
this is deemed necessary. 
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5.3 Companion diagnostics  
Many drugs that are part of personalized medicine require a diagnostic test to 
distinguish between those patients who benefit from a targeted therapy and those 
who do not. For this purpose, genetic testing is often performed to determine for 
example mutations or overexpression of certain genes. Results of these tests are 
crucial for further treatment. Therefore, it is extremely important that 
performance, safety and sensitivity of the test are reliable. Otherwise, the patient 
group is stratified incorrectly, which may result in individual patients receiving 
unnecessary therapy, which is ineffective in them and might even harm them and, 
on the other hand, patients who require a particular therapy that is withheld from 
them. The diagnostic devices that are capable of determining what therapy is 
suitable for a particular patient are referred to as “companion diagnostic”.147  
The legal framework of those very important diagnostic tests is rather weak; the 
legislation is lagging behind the technological development. Various aspects of 
this topic are repeatedly discussed. These are, for instance, the co-development for 
medicinal product and diagnostic device as well as the reimbursement situation. 
As different directives apply for drugs and diagnostic devices, co-development is 
challenging. Furthermore, the current legislation is not yet familiar with the 
concept of companion diagnostic. There is, to this point, no definition in the 
European Union of “companion diagnostic”, which makes handling them quite 
difficult. Another problem is the question of reimbursement. Although for many 
drugs the SmPC requires, or at least advises, a diagnostic test, not all tests are 
covered by health insurances. This could pose a problem for the future 
development of drugs and their companion diagnostic. Only proper 
reimbursement policies make the research and development of these technologies 
economically interesting. However, now this is still an unresolved matter. Today, 
the evidence level of many companion diagnostic and biomarker test is not yet 
strong enough to justify coverage from the GKV.  
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Further prospective, randomized studies must be conducted in order to increase 
the degree of evidence of these tools.148 Only when the tests prove that they can 
be used cost-effectively and are beneficial for the patients, thus are part of 
evidence-based medicine, the matter of reimbursement can be adequately decided. 
Another problem with drugs, that require a test for a particular characteristic prior 
to starting therapy, are the terms on how to apply such a test. For example, before 
trastuzumab can be administered, proof of the HER2 overexpression must be 
provided, which is actually a standard procedure for most breast cancer patients. 
Instead of appointing a specifically validated test to detect the overexpressed 
gene, the German Fachinfo (medicinal products professional information, SmPC) 
lists various methods that should be used for determination, such as an 
immunohistochemistry (IHC) of fixed tumour blocks for HER2 overexpression or 
Fluorescence in-situ hybridization (FISH)/Chromogenic in-situ 
hybridization (CISH) for gene amplification. The standards for laboratories that 
analyse the patient probes are rather imprecise. The text simply states: “To obtain 
accurate and reproducible results, the testing must be performed in specialized 
laboratories, which can ensure validation of the test methods.”149 As success and 
failure of such therapies strongly depend on the results of diagnostic tests, such a 
relatively broad description of standards should be viewed critically. Testing 
methods and their results do vary between laboratories and between the tests that 
are carried out. To achieve optimal and reliable results for patients, physicians and 
payers, it would certainly be advantageous if a particular test, a companion 
diagnostic, which was developed in advance to match the specific drug therapy, 
would be determined in the label of the drug. 
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In an ideal framework for the future, regulations and development of drugs and 
companion diagnostics would go hand in hand. That means  
1. joint development and clinical studies 
2. joint approval and  
3. joint reimbursement of medicinal product and companion diagnostic. 
This chapter shall give a general overview on regulations of medical devices and 
companion diagnostics in particular. At present, a revision of the existing legal 
situation is in progress. Differences between the current and the proposed new 
situation will be examined in respect to the new technological development of 
companion diagnostics. In general, the EU is trying to increase safety and 
transparency of medical devices, and to take into account the evolvement of new 
technologies. In addition to the European regulations, the US FDA’s view 
concerning companion diagnostics is presented.  
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5.3.1 Current diagnostics regulation 
Existing legislation of medical devices consists of three directives: 
• Directive 90/385/EEC on active implantable medical devices (AIMDD) 
• Directive 93/42/EEC on medical devices (MDD) 
• Directive 98/79/EC on in vitro diagnostic medical devices (IVDD) 
Directive 98/79/EC on in vitro diagnostics (IVDD) came into force on December 
7, 2003. The Directive defines ‘in vitro diagnostic medical device’ as  
“any medical device which is a reagent, reagent product, calibrator, 
control material, kit, instrument, apparatus, equipment, or system, whether 
used alone or in combination, intended by the manufacturer to be used in 
vitro for the examination of specimens, including blood and tissue 
donations, derived from the human body, solely or principally for the 
purpose of providing information: 
 concerning a physiological or pathological state, or 
 concerning a congenital abnormality, or 
 to determine the safety and compatibility with potential recipients, or 
 to monitor therapeutic measures.”150  
The Directive distinguishes five categories of IVDs:  
1. High risk devices listed in Annex II List A  
2. Moderate risk devices listed in Annex II List B 
3. Devices for self-testing intended to be used by lay persons in a home 
environment 
4. Devices for performance evaluation, meaning studies in laboratories for 
medical analyses 
5. All other devices not listed in Annex II and not intended for self-testing.151  
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Annex I lists all the requirements that a device that falls within the scope of the 
Directive must meet. These requirements are known as Essential Requirements. 
5.3.2 Prospective diagnostic regulation 
In the past 20 years, the European Union has grown and consists now of more 
Member States as the original directives came into force. Globalization and the 
enormous progress of technology and health care in the field of devices and 
diagnostics made a revision inevitable.152 
On September 26, 2012, the European Commission has unveiled drafts for a new 
medical device regulation and a new regulation on in vitro diagnostics, which are 
to replace the existing Medical Devices Directives (90/385/EEC on active 
implantable medical devices, 93/42/EEC on medical devices and 98/79/EC on in 
vitro diagnostics). The regulations are scheduled to enter into force in the years 
2015 to 2019. In contrast to the previous directives, the new regulations are 
directly applicable and therefore require no more implementation by the Member 
States’ laws. Instead of three directives the new medical device legislation will 
consist of two regulations, one covering in vitro diagnostics and the second one 
will cover both medical devices and active implantable medical devices.  
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Current Legislation 
 
Prospective Regulation 
Directive 90/385/EEC 
(AIMDD) 
EU Regulation 
Medical Devices 
 
Directive 93/42/EEC (MDD) 
  
Directive 98/79/EC (IVDD) 
 EU Regulation 
In vitro Diagnostics 
 
According to the Commission, the change of the legal form was necessary, as the 
implementation of the Directives into national law was inconsistent. Monitoring 
of devices and diagnostics, which is so far only a national issue, will partly be 
taken over by the Commission.  
Due to the enormous developments in technology and on the health care market, 
revision of the over 20 year old directives is urgently needed. The “PIP breast 
implants scandal” of 2010 was another driver for changing regulations. The 
French implant manufacturer, Poly Implant Prothèse (PIP) had produced implants 
of inferior quality using unapproved silicone gel with intend to defraud. The 
substandard implants hold a higher risk of rapture than those of good quality. 
Leakage of silicone can lead to local tissue irritations or inflammation. Leaked 
silicone may be distributed through the whole body and can accumulate in lymph 
nodes. Hundreds of thousands of women who had received those implants were 
urged to consult their doctors in order to check for ruptures. After the first defects 
became public, the French competent authority, Afssaps, was the first European 
agency to withdraw PIP implants from the market. The agency discovered the use 
of substandard silicone and the non-compliance with regulations and 
manufacturing specifications before the German Notified Body in charge, TÜV 
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Rheinland.153,154 The Notified Body therefore bears part of the blame according to 
an initial French court decision.155 The German court referred the case to the 
Court of Justice of the European Union to clarify responsibilities of Notified Body 
and further question in regards to the MDD and patients safety.156 The immense 
media coverage of the topic and the high number of affected patients draw the 
politics’ attention to the matter of device regulation.  
 
5.3.2.1 In vitro diagnostics 
As for medical devices, one of the most important novelties is the change of the 
legal form from directive to a regulation, which is directly binding for all Member 
States. The Regulation  
“aims to ensure the smooth functioning of the internal market and a high 
level of protection of human health and safety“  
as well as to  
“overcome […] flaws (of the current directive - author’s note) and 
divergences and to further strengthen patient safety”.157  
The new Regulation proposal (EC proposal for a regulation of the European 
Parliament and of the Council on in vitro diagnostic medical devices) is largely 
based on the currently existing IVD Directive 98/79/EC yet the scope of the 
Regulation is clarified and extended concerning the following aspects to cover the 
most recent technological achievements:  
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 high-risk devices manufactured and used within a single health 
institution, which are subject to most of the requirements set out in 
the proposal; 
 tests providing information about the predisposition to a medical 
condition or a disease (e.g. genetic tests) and tests providing 
information to predict treatment response or reactions (e.g. 
companion diagnostics), which are considered as in vitro 
diagnostic medical devices; 
 medical software, which is explicitly mentioned in the definition of 
IVDs.157 
The EC states, that the proposal intents to support innovations and 
competitiveness as well as faster, more cost-efficient market access. 
A new requirement in the proposal of the EC is the “qualified person” on the 
manufacturer’s side to ensure compliance with quality management and 
regulations. Since traceability has always been a problem with the current 
Directives the EC introduces a Unique Device Identification (UDI), a numeric or 
alphanumeric series, which IVDs are required to be equipped with, thus 
increasing transparency and patient safety. To further increase transparency, the 
European databank on medical devices (Eudamed) is to be expanded and include 
more information about the medical devices and made publicly available in large 
parts. Strengthening the competences of the Notified Bodies is one more subject 
to improve the system’s quality. NBs are to carry out unannounced inspections.158 
Monitoring of the Notified Bodies itself will be taken out by the Member State’s 
national authorities, and, in intervals, by a joint assessment with experts from 
other Member States and the Commission. A new classification system for IVDs 
will divide them into four risk classes (A, B, C, D) with class A being the lowest 
class of risk and D presenting the highest risk. This classification follows the 
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suggestions of the IMDRF (International Medical Device Regulators Forum, an 
organization, which replaces the former Global Harmonization Task Force 
(GHTF)). Conformity assessment of class A diagnostics can be carried out by the 
manufacturer, unless the IVD is intended for near-patient testing, has a measuring 
function or is sold in sterile condition. In that case, involvement of a NB is 
essential. Depending on their risk class, varying degrees of Notified Body 
involvement is required for devices of class B, C and D. For class B and C the 
quality management system is revised, for class C the technical documentation of 
representative samples is checked additionally. Devices of class D require 
approval of design and quality management prior to the placement on the market. 
A “real” authority based approval process, as it is established for the authorisation 
of medicinal products, will not yet be realized in the near future in the European 
Union, although this is being demanded by some stakeholder (such as the German 
associations of the statutory health insurance, GKV Spitzenverbände)159. The 
regulations are rather an evolution of the existing legal framework than a radical 
restructuring of the medical devices landscape. Nevertheless, the new regulations 
are expected to improve patient safety by strengthening the power of Notified 
Bodies, more competences for the EMA and the formation of the MDCG 
(Medical Device Coordination Group within the EMA). Industry benefits from the 
conditions; an approval similar to those of drugs, would be associated with higher 
costs than the upcoming solution, even if individual products are classified in a 
different product class. It is often argued that a medical device approval could 
slow down their market entry (due to a lack of capacity on authorities’ level as 
well as longer, stricter and costlier trials) so that it will take longer for patients to 
gain access to innovations. The new Regulations should therefore be regarded as a 
compromise between an innovation stimulating, cost-effective system and a 
higher patient safety that strengthens the Commission as a supervisory body and 
harmonizes standards. 
                                                 
159
 Spitzenverband der gesetzlichen Krankenkassen. Medizinprodukte – Mythen und Wahrheit: 
Gemeinsames Argumentationspapier von den Spitzenverbänden der gesetzlichen Krankenkassen 
in Deutschland. 2013 [Accessed on: 26 Jun 2016]. http://www.aok-
gesundheitspartner.de/imperia/md/gpp/bund/krankenhaus/meldungen/medizinprodukte_thesenpapi
er_krankenkassen.pdf. 
5 Applications of therapeutic concepts 
 
 93 
 
5.3.3 Companion Diagnostics 
Companion diagnostics will be covered in the proposed Regulation on in vitro 
diagnostic medical devices. Among other new definitions in the proposal, the 
important definition of companion diagnostics (CDx) was long expected. The 
initial proposal by the European Commission defined companion diagnostic as 
follows: 
‘Companion diagnostic’ means a device specifically intended to select 
patients with a previously diagnosed condition or predisposition as 
eligible for a targeted therapy.157 
This first proposal of a definition by the Commission was amended in the 
Parliament on October 22, 2013 and gives now a narrower, more specific 
definition: 
‘companion diagnostic’ means a device specifically intended for and 
essential to the selection of patients with a previously diagnosed condition 
or predisposition as suitable or unsuitable for a specific therapy with a 
medicinal product or a range of medicinal product.160  
Changes in the original definition and the amended definition are pointed out in 
bold font. The revision of the definition responds to criticisms that saw the first 
definition as too soft. The definition of the Parliament seems to be less broad than 
the proposal of the Commission. In the revised version, it is clearly emphasized 
that the device does not only select patients, but that this selection must essential 
for the subsequent treatment, which is a narrower scope. In addition, eligible is 
replaced by suitable or unsuitable to specify the intended use. The rather neutral 
term “targeted therapy”, that does not explain the kind of therapy that can be used, 
is reduced by the Parliament to therapy with a medicinal product or a range of 
products. Thus, the Parliament would like to express the fact that a device can 
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only be a companion diagnostic when the device is essential to the patient 
selection and that therapy of selected patients is carried out with (a) medicinal 
product(s). This stricter definition takes into account that the correct diagnostic is 
extremely important for therapy with targeted agents. 
In the current legislation, where a definition of companion diagnostics does not 
exist, these devices usually fall under the scope of the IVDD.  
Companion diagnostics are categorized in the new classification system as class C 
medical devices (Annex VII point 2.3) that present a high risk for the patient and a 
low public risk. This means that a Notified Body will be involved in the 
conformity assessment and examine the design of the companion diagnostic. 
Annex VIII of the proposal describes the examination. The Notified Body shall 
consult with the competent authority or the EMA regarding the suitability of the 
device in relation to the medicinal product concerned. Consultation with the 
competent authority or EMA shall also apply when changes are made to the 
device. Amendment of the Parliament states that companion diagnostics shall only 
be supplied on a medical prescription. Clinical evidence as well as vigilance and 
market surveillance are firmly embedded within the proposal to enhance safety 
and support intended use of the product.  
5.3.4 FDA approach for companion diagnostics 
The approach used by the FDA to handle in vitro companion diagnostics differs 
from the way used in Europe. Guidance for industry and FDA staff on in vitro 
companion diagnostic devices was released in August 2014 (draft in July 2011) to 
clarify the FDA’s opinion on the issue.161 The guidance addresses sponsors who 
are developing a product that depends on the result of a diagnostic test and 
developers of in vitro diagnostics that are to be used with a particular therapeutic 
product. Recently, with more and more therapies and medications being 
developed that are dependent on the result of a diagnostic test for a safe and 
effective use, the FDA thinks that this subject should be sufficiently regulated. 
Incorrect test results can lead to the treatment of patients who do not benefit from 
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the therapy and a greater risk of adverse effects. Therefore, it is important that 
health care professionals can rely on test results to enhance treatment. The FDA 
defines a companion diagnostic as  
“an in vitro diagnostic device that provides information that is essential 
for the safe and effective use of a corresponding therapeutic product.”161 
This definition differs slightly from that of the EU as it explicitly mentions a 
corresponding therapeutic product and lacks the statement that the device is used 
for patient selection but specifies that it is used to provide information on a 
therapy. An inaccurate test can mean that the corresponding product is 
administered to the wrong patient or is denied the right patient. The correct 
interaction of IVD companion diagnostic device and pharmaceutical is therefore 
extremely important to identify patients who benefit and those who will not, 
recognize which patients might be at a higher risk for serious adverse reactions, or 
monitor therapy response correctly. The corresponding IVD companion 
diagnostic device will be reviewed by the FDA and approved or cleared, 
depending on the regulatory requirements of the device. The FDA has two 
different processes to handle medical devices: 
 Premarket approval (PMA) 
 Premarket Notification (510k) 
Three classes for medical devices exist. Class I devices usually present a low risk 
and therefore in most cases no regulatory approval is required. However, class I 
devices and the manufacturer must be listed. Class II devices have a higher risk 
than Class I and Class III devices is the highest risk classification with high 
regulatory control.162 Premarket approval (PMA), the most stringent type of 
device marketing application, is used to evaluate most Class III devices, those 
devices that hold a high risk such as support or sustain human life, are of 
substantial importance in preventing impairment of human health, or which 
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present a potential, unreasonable risk of illness or injury.163 Before such a device 
is put on the market, the manufacturer must seek approval by PMA application. 
PMA approval is received when the FDA believes the scientific evidence 
sufficiently supports the safe and effective use for its intended purpose. The 
application must therefore contain information about design and manufacturing 
process. Data of preclinical (e.g. biocompatibility) and clinical studies are 
required too. For devices of Class I, II or III that do not require a PMA a 
Premarket Notification must be submitted. Premarket Notification (PMN) is also 
known as 510(k), named after the CRF section for this procedure. This should be 
done at least 90 days before marketing. Most Class I and some Class II device are 
exempt from 510(k). In the 510(k) process FDA evaluates if the device is 
“substantially equivalent” to a legally marketed device that is not subject to PMA. 
Substantial equivalence is defined as “at least as safe and effective as [a] 
predicate”. 164 That means the new device must be equivalent, not identical, in 
terms of “intended use, design, energy used or delivered, materials, chemical 
composition, manufacturing process, performance, safety, effectiveness, labelling, 
biocompatibility, standards, and other characteristics, as applicable.” Devices that 
are marketed under a 510(k) are not approved like under PMA but cleared.  
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Table 8 Comparison of the FDA’s 510(k)/Premarket Notification process and the Premarket 
Approval/Investigational Device Exemption.163,164  
510(k)/PMN  PMA 
Most commonly used for some Class I 
and most Class II devices (also some 
PMA exempt Class III) 
 Mainly for Class III device 
Clinical study rarely required   Clinical study required  
“Substantial equivalence” to a legally 
marketed device must be demonstrated 
 
Safety and effectiveness for intended use 
must be demonstrated 
Device is cleared for commercial 
distribution by the FDA 
 
Device is approved by the FDA prior to 
marketing 
 
Clearance or approval of the IVD companion diagnostic device is done under 
device authority and will be reviewed within the context of the corresponding 
therapeutic product. FDA suggests co-development for novel therapeutic products 
and IVD companion diagnostic devices when test results are crucial for safe and 
effective use of the therapeutic. It will therefore be determined whether the device 
is well validated and meets all required standards. Apart from a few exemptions, 
the FDA will not approve any novel therapeutic products without having cleared 
or approved a suitable validated IVD companion diagnostic device first for the 
intended indication when the safe and effective use of said product depends on the 
test results.161 Exemptions to this regulation may be, for example, pharmaceutical 
products for serious or life-threatening diseases. In that case, when no satisfying 
treatment alternative exists, approval of a particular product without an approved 
or cleared IVD may be possible when the benefits from the use with an 
unapproved or not cleared IVD outweigh the risks. However, a suitable IVD later 
on shall be sought to be approved or cleared. Thus, the FDA generally expects 
that IVD companion diagnostics are considered in the novel therapeutic product 
development as they intend to approve/clear both at the same time. For industry 
that means, IVD and drug development should go side-by-side, co-development 
should start as early as possible. An IVD need not necessarily be new, but can 
also be a modified, already existing IVD. Nevertheless, the same regulations 
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apply for that IVD, as its intended use with a novel therapeutic product is a major 
change from the one already existing. 
Companion diagnostics to determine a patient’s likelihood to respond a certain 
therapy are for example approved for Xalkori (crizotinib) and Zelboraf 
(verumafenib). Zelboraf is a drug intended to treat patients with late stage or 
unresectable melanoma. The cobas 4800 BRAF V600 Mutation test was approved 
along with the drug to identify patients with mutated BRAF V600E. Only patient 
with a positive mutation test outcome are to be treated with Zelboraf, as the drug 
has not been studied with BRAF protein mutation negative patients.165 Xalkori is 
used for the treatment of late stage, non-small cell lung cancer. Before a patient 
receives the treatment it is necessary to test if the patient expresses the abnormal 
anaplastic lymphoma (ALK) gene, as the drug is only to be administered to 
selected patients with abnormal ALK gene. To determine this group of patients, 
the FDA approved the Vysis ALK Break Apart FISH Probe Kit approved together 
with the drug under its priority review program.166 Both drugs and their test were 
approved in August 2011. A FDA approved device can be used only for the 
specific intended use. For example, a test for the detection of a mutated KRAS in 
colorectal cancer patients cannot simply be used to test for mutated KRAS in lung 
cancer. It is imperative that each test is validated for its intended use in a new 
process.167  
  
                                                 
165
 FDA. FDA approves Zelboraf and companion diagnostic test for late-stage skin cancer. 17 Aug 
2011 [Accessed on: 26 Jun 2016]. 
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm268241.htm.  
166
 FDA. FDA approves Xalkori with companion diagnostic for a type of late-stage lung cancer. 26 
Aug 2011 [Accessed on: 26 Jun 2016]. 
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm269856.htm.  
167
 Marton MJ, Weiner R. Practical guidance for implementing predictive biomarkers into early 
phase clinical studies. Biomed Res Int. 2013;2013(4):1–9. 
6 Implementation: approval of “therapeutic concepts” in Europe 
 
 99 
 
6 Implementation: approval of “therapeutic concepts” in 
Europe 
Therapeutic concepts combine ideas and knowledge from different areas. 
Particularly the developments in personalized medicine pave the way for a 
systematic development for authorised combinations because a patient population 
for which the therapeutic combination is beneficial can be determined on a 
scientific basis. This way, the “biological rational” that is required by guidelines 
and regulations on medical combinations can be met.  
By introducing therapeutic concepts, diagnostics, which are indispensable for 
personalized medicine, can be included in an approved therapy. The 
pharmaceutical – diagnostic combination shall be studied in clinical trials to 
eventually include a test, which is demonstrably valid. Medical devices that 
incorporate a medicinal product are regulated under the medical device directive 
when the pharmaceutical constituent provides solely ancillary action for the 
medical device. Similar to this approach, therapeutic concepts would offer the 
opportunity to authorise a medical device in combination with a pharmaceutical 
under the medicinal product regulation, as the medical device is supportive and 
informative in the administration of the medicinal product.  
From the beginning of their marketing, the therapeutic concept is a treatment 
combination, comparable with the recommendations of medical guidelines, but 
with a joint development and approval that support the safe application. 
Additional input for the implementation of therapeutic concepts is provided by 
FDA guidance with recommendations for the co-development of already 
marketed drug in combination. Further considerations and approaches for the 
implementation of therapeutic concepts are outlined in the following sections. 
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Figure 8 Components that influence the development of therapeutic concept: Medical guidelines, 
evidence and experience gained from personalized medicine and companion diagnostic research 
as well as current views on co-development of therapies.  
 
6.1 Clinical trials  
Non-clinical and clinical investigations are as important for therapeutic concepts 
as they are for any other medicinal product and are the standard for the evaluation 
of benefits and risks. Exceptional emphasis must be made on the interaction of the 
different components of the therapeutic concept to consider possible additional 
risk derived from the combination, especially those of the combination of two or 
more pharmaceutically active substances. Non-clinical studies should be carried 
out jointly as far and as soon as possible. Clinical trials for therapeutic concepts 
must furthermore be well designed to address the additional risks and interactions 
arising from the combination but also the benefits of the combination in contrast 
to monotherapy or standard of care must be demonstrated. The FDA has issued 
guidance for co-development of drugs, which can serve as guidance in the design 
of therapeutic concepts clinical trials as well. 
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6.1.1 Design of clinical trials for combination use 
FDA acknowledges the need for combination therapy in certain conditions and 
encourages co-development of drugs. They released draft guidance168 in 
December 2010 concerning the co-development of novel unmarketed drugs for 
use in combination and a final guidance for industry on this topic in June 2013.169 
Before the FDA released this guidance, co-development of drugs for a 
combination regimen was rather challenging as no further assistance in this matter 
existed. The concept of combination treatment is not new of course but the FDA 
guidance gives precise requirements and recommendation on how the 
development should proceed. Regulatory, scientific and medical aspects are 
addressed. Having a guidance that highlights the importance of drug combinations 
helps to speed up drug development and reduce costs. It also helps patients gain 
earlier access to treatment.170  
The guidance states, that for many serious diseases such as cancer, infections and 
cardiovascular diseases “combination therapy is an important treatment 
modality”. Growing understanding of pathophysiological mechanisms helps 
improving treatment responses using drug combinations. New therapeutic 
approaches based on this knowledge can be used to our advantage. Due to a 
higher risk of those combinations compared to single drug use alone combinations 
should only be developed for serious diseases. Knowledge of the individual active 
compounds in the combination is lower than that of only one active ingredient 
developed for the treatment. Therefore, the data concerning the safety profile, 
effectiveness and dose-response are less informative. The FDA therefore specifies 
the conditions under which co-development is reasonable. Criteria for developing 
such new combinations are very similar to the ones mentioned in the EMA 
guideline on fixed combination.  
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 The combination is intended to treat a serious disease or condition 
 There is a strong biological rationale for use of the combination (e.g. 
inhibition of different pathways, lower doses of drug can be administered 
to decrease toxicity, resistances are reduced) 
 A full non-clinical characterization of the activity of both, the combination 
and the individual new investigational drugs, or a short-term clinical study 
on an established biomarker, suggests that the combination may provide a 
significant therapeutic advance over available therapy and is superior to 
the individual agents. A non-clinical model should demonstrate that the 
combination has substantial activity and provides greater activity, a more 
durable response (e.g., delayed resistance), or a better toxicity profile than 
the individual agents. 
 There is a compelling reason why the new investigational drugs cannot be 
developed independently (e.g. risk of resistance, limited activity when 
used as monotherapy).169 
Furthermore, the procedure for clinical development is described in the guidance. 
The main objective in Phase 1 studies is to determine safety and pharmacokinetics 
of both the individual drugs and the combination. Whenever feasible, all 
pharmacokinetic parameters of the individual drugs should be investigated. If it is 
not possible to characterize the drugs individually in humans, non-clinical studies 
should be conducted. Phase 2 should further demonstrate the contribution of each 
individual new investigational drug in the combination, provide evidence of the 
combination’s effectiveness and adjust the dose(s). When possible a factorial 
study design is desirable to obtain as many information about the drugs and their 
combination.  
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Three scenarios are conceivable for phase 2 studies: 
1. Each new investigational drug alone has activity and they can be 
administered separately 
To obtain the most information about safety and effectiveness the individual drugs 
alone should be compared to the combination and standard of care (SOC). 
2. The individual new investigational drugs in the combination cannot be 
administered separately 
In cases where the individual drug cannot be administered separately for 
pharmacological or ethical reasons (e.g. ineffectiveness of the individual drug or 
rapid development of drug resistance) only the combination should be studied. 
3.  When administered separately, one new investigational drug in the 
combination is active and one is inactive 
The minimally active compound requires Phase 1 safety studies but not a further 
individual drug Phase 2 study. 
The study designs suggested by the FDA for each scenario are given in Table 9. 
Table 9 Study design of Phase 2 studies in co-development of two unmarketed drugs according to 
FDA. A and B indicate the different active compounds of the combination. 
Scenario Study design Remarks 
1 
A v. B v. AB v. SOC or 
placebo 
SOC can be added to each arm, when it 
is a known effective, not palliative, 
therapy 
2 AB v. SOC 
SOC can be added to AB, when it is a 
known effective, not palliative, therapy, 
comparing to placebo + SOC 
3 
A* v. AB+ v. SOC or 
placebo 
 
*active drug, + inactive/minimally active drug 
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The study design of phase 3 confirmatory studies depends on the results of phase 
2 studies. If the data suggest that the combination is superior to individual use and 
the role of each new investigational drug can be demonstrated, it is feasible to 
compare the combination to standard of care or placebo. If data for the 
contribution of each individual drug cannot be provided, a factorial design similar 
to scenario 1 or 3 (see above) would apply. However, these are case-by-case 
decision depending on previously obtained results.  
The industry welcomed the guidance as it helps them to meet regulatory and 
scientific requirements in modern drug development. Especially the proposed 
study design for phase 3 studies helps to conduct more efficient trials as different 
situations in the drug development process can be handled flexibly. When the 
contribution of each drug of the combination is demonstrated in phase 2 a two 
arms study design for the combination is suggested. Prior to the publication of the 
guidance, a three or four arms study with the individual drugs and the 
combination was usually required. Therefore, industry benefits from more 
efficient clinical studies in terms of time and costs because trials will not have to 
have multifactorial design investigating three (four) arms, placebo, combination 
and single agent(s), but only two arms comparing combination to placebo or 
standard of care.15,171 Shorter development times mean faster market access and 
patient access. Consequently, patients benefit greatly from the guidance’s outline.  
A major disadvantage is of course a smaller knowledge about the single agents in 
the combinations, which leads to a higher risk factor. This uncertainty can only be 
accepted when treating serious diseases with little treatment alternatives. For this 
reason, a strong focus on safety aspects is present in the FDA guidance.  
The FDA guidance is a good starting point for introduction of therapeutic 
concepts. Especially the study design of non-clinical and clinical development is a 
solid basis.  
However, the guidance only concerns novel unmarketed drugs. Nevertheless, it 
can be expected to be found that also drugs that are already marketed can be 
beneficial in certain combination therapies for specific indications. Therefore, the 
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FDA guidance takes a step into the right direction but does not go far enough yet. 
Therapeutic concepts on the other hand would take the next step and would cover 
combinations containing compounds that are already marketed to improve the 
safety of combinations use of these compounds.  
6.2 Benefits and challenges 
Reassessment of the current approval processes is vital for a continuous 
improvement of the entire system. New approaches are advantageous when they 
provide benefits for at least one interested group. In the regulatory system of the 
health care sector, several stakeholders have to be considered before new 
processes are introduced namely the industry, patients, payers, health care 
professionals and regulatory authorities. A new regulatory pathway towards 
therapeutic concepts would influence all stakeholders, thus the potential benefits 
of the proposed regulation are discussed as well as possible difficulties. The 
question in regard to the advantages and disadvantages is who would benefit from 
therapeutic concepts compared to other combination possibilities such as medical 
guidelines and fixed combinations and which changes arise for the different 
stakeholders.  
 Industry 
Therapeutic concepts would pose an entirely new challenge for the 
pharmaceutical industry. However, therapies in which several medicinal 
products or medical devices are involved are standard in many cases 
nowadays and a certain interest in the regulation of combinations is 
present. A defined regulation on therapeutic concepts would offer 
guidance for the industry for the development of such. After identification 
of targets, the clinical testing could become more efficient if clear rules 
would exist. Possible clinical trial scenarios are described in Chapter 6.1.1 
which would provide fewer costs and smaller trials if only the superiority 
of the combination must be proven against placebo or standards of care 
and not in a three-armed study. That results in faster access to market for 
combinations under the therapeutic concept approach. A further possible 
benefit for industry would be the marketing of already marketed drug in 
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new indications as a combination therapy. If an already marketed product 
is found to be more effective in a certain combination with other products, 
this could expand the indication of the product and might results in new 
marketing possibilities and increasing profits.  
 
 Patients 
One of the biggest benefits that patients will gain from therapeutic 
concepts are therapies with combinations that have been studied and 
developed precisely for this purpose which means higher safety for the 
patients and possibly less side effects due to stratification and identified 
contraindications. Therapeutic concepts might even be increasing 
compliance by giving the patient the possibility to identify oneself with the 
regime more when the combination is clearly stated in the labelling for a 
certain disease (see also Chapter 6.3).  
The patient does not have a direct benefit by simplified administration, as 
it is the case for fixed combinations but may profit from a more flexible 
dosing. 
 
 Agencies / Regulatory authorities 
With the evolving medical knowledge therapeutic, standards change 
rapidly. At times, treatments become the standard of care even if they are 
not approved for it. This possibility is particularly given to the field of 
pharmacogenomics and personalized medicine because the knowledge of 
signalling pathways, toxicity and cell interactions is growing rapidly in 
this area and sensitive tests enable diagnosis that is more accurate. 
Combination therapies, which are novel in this particular combination can 
be considered as medically reasonable under the gained understanding. A 
treatment of this kind would not be approved but can be regarded as 
intended use over time nonetheless. On the other hand, an approved 
intended use of a product may prove obsolete due to new findings. In both 
cases, therapeutic concepts provide a new possibility for authorities to 
respond to such changes.  
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With the approval of therapeutic concepts, different products would be 
combined with one another through the marketing authorisation and must 
therefore be used in this designated combination for a defined indication. 
Medical guidelines in contrast only recommend a therapeutic combination 
of products, which is not directly mandatory from the legal point of view. 
Therapeutic concepts are therefore considered to have a more binding 
character than guidelines. Compared to fixed combinations therapeutic 
concepts offer more flexibility with respect to patient needs. As the 
products of the combination are available separately, even products with a 
narrow therapeutic range or dosing according to body surface could be 
approved within a therapeutic concept. Disadvantages of fixed 
combinations such as unequal duration of action and interactions in 
metabolism can be compensated with the use of therapeutic concepts with 
administration in intervals or dosage adjustments. The advantages of fixed 
combinations such as enhancement of action and better effectiveness and 
possible mitigation of side effects are retained. 
Regulatory authorities ensure that only safe and effective products are 
released into the market. The same is true for the safety and efficacy of 
therapeutic concepts. Authorising this new regulatory approach gives the 
agencies the chance to strengthen their position in the control of 
combinations used. Should there be any concerns about the safety of a 
therapeutic concept that has been revealed in clinical trial or in post market 
surveillance or vigilance reports the authorities will be able to react fast in 
case of a serious risk to public health. They will be able to withdraw or 
suspend the marketing authorisation in order to minimize risk for the 
public or create a negative list for high-risk combinations. 
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 Payers 
Therapeutic concepts could result in savings of health care costs in the 
long term. Comparable to cost-effectiveness evidence in personalized 
medicine it will be difficult to determine potential savings in the 
beginning, as cost may rise first since payers would be paying for the 
entire therapeutic concept, including any diagnostics that would be part of 
the concept. However, due to more effective therapies with lower 
incidence of adverse reactions and associated follow-up costs the higher 
initial costs can be justified. Approved therapeutic concepts form a new 
treatment standard that might turn out as superior to other treatments 
already in the clinical trials prior to authorisation, which is much earlier 
than those combinations that are evaluated in medical guidelines. 
Combinations described in medical guideline are often the results of years 
of experience and studies with the products before they are included in a 
guideline. Therapeutic concepts can hence set a new standard very early in 
their life time cycle that might prove as cost-effective.  
 
 Health care professionals 
For health care professionals it is always important to provide the best care 
to their patients. New therapeutic concepts would mean that the 
combination of products used is well-studied. It therefore provides more 
security for physician when prescribing such a therapy. An approved 
therapeutic concept would create a greater legal certainty as well as a more 
efficient treatment compared to medical guidelines especially those of 
lesser quality. Therapeutic concepts that consist of a drug and a medical 
device or diagnostic may be easier applied, as reimbursement for the entire 
therapeutic concept should be provided. Today, diagnostic and drug are 
often considered separately by payers when it comes to cost coverage so 
physician sometimes struggle to get the right diagnosis for their treatment 
choice. Compared to fixed combinations physician are able to be more 
flexible with the therapy and can for example adjust dosage in patients 
with renal or hepatic impairment.  
Despite the various opportunities offered by therapeutic concepts there are 
also challenges that need to be faced which are related primarily to the pre-
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clinical and clinical development. It is conceivable that several 
pharmaceutical companies will have to work together in the development 
of a combination regimen, which can be regarded as a potential source of 
conflict. In a drug-drug combination the developers need to assess the 
single agents and their contribution to the overall effect and evaluate if one 
of the drugs shows a significantly more effective or toxic effect.171 Results 
from such considerations may not only affect the development process and 
decisions which company will cover which part of the total costs. It will 
also have considerate influence on pharmacovigilance plans and risk 
management.  
Evaluation of therapeutic concepts in which one or more drugs are to be 
applied in different dosage strengths depending on individual patient 
characteristics will be a further challenge. For industry and agencies, 
planning and evaluation of clinical trials that include several dosages to 
prove safety and efficacy can become a complex matter. It must be 
considered whether all strengths in the therapeutic concept offer benefits 
and safety. 
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Table 10 Summary of benefits provided by therapeutic concepts 
Benefits of therapeutic concepts 
 More flexible and individual dosing in combination therapies 
 More effective treatment by approved standards 
 Closing the gap between treatment realities and legal framework 
 Reimbursement of all parts of the therapeutic concept possible 
 More control on combinations in use for authorities 
 More studies on the combination use 
 Reduction of side effects by patient stratification, available studies and 
dosage adjustments 
 New marketing opportunities for industry 
 
6.3 Labelling and Packaging 
Labelling and packaging is an important part of any medical product. It must be 
made clear what the drug’s intended use is and how it should be used. This applies 
also to drugs that are meant to be used as a therapeutic concept. Labelling must 
clearly state what the therapeutic concepts consists of and how the combination is 
used. Products belonging to the therapeutic concept do not necessarily need to be 
part of a combination pack, nor are they intended to be a fixed combination, thus 
meaning that there is no requirement for the drugs to be part of a single product 
package. The whole idea of the concept is to give physicians the freedom to adapt 
the right dose for each patient and having a combination pack would limit this 
freedom since it might not contain the drugs in the right dose for the patient. 
Additionally, for some therapeutic concepts the patient population might even be 
so small due to stratification that making a combination pack would be too much 
of an effort for industry. 
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Labelling of drugs that hold a marketing authorisation as a therapeutic concept 
presents several options depending on how the drugs of the therapeutic concept 
are marketed and whether they are only used in an approved combination or are as 
well used in other indication. Therefore, the following three scenarios are 
possible: 
1. The drugs or drug/diagnostic combination are only to be used within the 
approved therapeutic concept 
2. One or more compounds of the therapeutic concept are also used 
individually for an approved purpose but sold under the same brand name 
3. One or more compounds of the therapeutic concept are also used 
individually for an approved purpose but sold under different brand names 
for individual use and use in the therapeutic concept 
According to the different case scenarios different labelling option should be 
applied. Generally, if the marketed drug is meant to be used within a 
therapeutic concept it should be pointed out explicitly in the labelling. That 
way it can be ensured that the patient is aware this is a deliberately chosen 
medical concept, in which the specific combination of drugs (and diagnostic, 
if needed) offers advantages in therapy. For the three scenarios mentioned 
above three different label approaches are possible: 
1. If the drugs are only marketed to be used within the approved 
therapeutic concept then only the use of the combination should be 
described in the package leaflet. The criteria for patient stratification 
should also be mentioned in the product information. Since the drugs 
of the combination can be sold separately, it should be made clear from 
the package leaflet that this drug is only to be used in the specific 
combination that has been developed and studied for.  
 
2. If drugs of the combination are also used individually for treating other 
indications than that of the therapeutic concept and both uses are 
marketed under the same brand name there should be separate 
prescribing information for each intended use. Conceivable in this case 
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scenario would be a dual concept of the package leaflet. The fact that 
the drug can be used either alone or in an approved therapeutic concept 
should be made clear for example by having two separate columns for 
each intention. Intended use, contraindications, adverse drug effects 
and all other important information should be described separately in 
each column, one for the individual use and one for the therapeutic 
concept use. Again, a remark about the specific combination use 
should be made and necessary stratification processes should be 
described. 
 
3. In a third possible scenario the drugs can either be used individually or 
in a therapeutic concept, similar to (2.) but the manufacturer might 
chose to market the drugs depending on their indication and use under 
separate brand names, one for individual use and one for the 
therapeutic concept. Labelling according to (1.) should be applied for 
the drug marketed as the therapeutic concept. For the drug marketed 
for individual use the general rules for labelling would apply. 
It could be considered to apply a special mark on the package leaflet that indicates 
that this medicine is designated for the use in a therapeutic concept. In 2013, the 
EMA has introduced a black triangle displayed on package leaflet for medicines 
under additional monitoring to raise the patient's attention. The meaning of the 
black triangle is explained in a short sentence.172 Similar to the black triangle 
mark the application of a different mark indicating the therapeutic concept, for 
example a “plus” (+) mark, would be possible. The mark and its explanation in the 
package leaflet would make patients and health care professionals conscious to 
the particular therapeutic situation. 
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6.4 Vigilance and risk management 
Having a new way of authorisation induces new challenges in pharmacovigilance. 
As has been described, combinations present a higher risk than a single agent does 
since knowledge about the single substances in the combination is smaller. The 
higher risk needs to be presented in vigilance plans. However, not all combination 
will hold the same risk, some combinations are riskier than others and therefore 
pharmacovigilance plans may vary. Different aspects should be considered when 
developing a risk plan, such as:  
 Are one or more substances of the combination already in use? If so, can 
these substances be considered as high risk or low risk? 
 Is it likely to administer other drugs with the combination? 
 Are drugs from the combination likely to be used individually? 
These are only some of the questions that need to be asked when discussing 
vigilance. Not all combinations will require more intense monitoring. Vigilance 
should therefore be a case-by-case decision and post marketing safety monitoring 
should best be discussed early with the agency. 
6.5 Reimbursement 
An important criterion for the success of any drug is the reimbursement policy. 
Without a proper reimbursement, most patients will not have access to certain 
therapies or medicines because the health insurance will not bear the costs. 
Therefore, early considerations about reimbursement are an essential part of any 
drug development.  
Reimbursement practices are not harmonized within the European Union. Each 
Member State decides which therapies are reimbursable and determines the 
standards on which this decision is based. In Germany, the Federal Joint 
Committee (Gemeinsamer Bundesausschuß (G-BA)) is responsible for 
determining which health care services are reimbursed for 70 million members of 
the German statutory health insurance (Gesetzliche Krankenversicherung 
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((GKV)).173 The G-BA is authorised by § 92 (1) 1 of the German Social Security 
Code V (Sozialgesetzbuch (SGB V)). The insured persons shall obtain a 
“sufficient, appropriate and economical” supply of health care services and 
products. Based on this definition the G-BA is able to restrict or suspend the use 
of certain products when it is found that there are other sufficient and more 
economical alternatives or when a treatment should be obsolete. This principle of 
efficiency was created to stabilize the health care system in the long term but it 
also creates a conflict potential from time to time. Patient representatives and 
pharmaceutical companies often find the decision not to reimburse a product 
questionable or unjustified. Annex III of the Guideline for Medicinal Products 
(Arzneimittel-Richtlinie (AM-RL)) gives an overview of the G-BA regulations on 
limitations and exclusions from reimbursement. Several fixed combinations can 
be found on this list, excluding them from reimbursement. Pharmaceutical with 
fixed combinations are often considered to pose a higher risk as the risk of side 
effects tend be higher and their interaction potential and effect on 
pharmacokinetics is often not extensively known. Additionally they are usually 
more expensive, thus less economic, than a free combination of several 
substances. The missing therapeutic benefit and medical need as well as the 
economic inefficiency, that are required in § 16 (1) AM-RL result in number of 
fixed combinations that are excluded by the list; for example analgesics with non-
analgesic substances like phenazone with caffeine (Annex III no. 6) and anti-
inflammatory drug with other substances (Annex III no. 18). However, there are 
exceptions to some restrictions, if a therapeutic benefit is proven. For no. 6, an 
exception is made for products with naloxone as such combinations have a strong 
pharmaceutical rational. An exception to no. 18 is the combination of naproxen 
(NSAID) with esomeprazole (PPI) that is marketed since 2012 under the trade 
name Vimovo. Studies indicate that 30 % of patients treated with NSAIDs 
develop dyspepsia and 10 % are affected by ulcers that might lead to serious 
complication.174 Therefore, administration of PPI as prophylaxis during NSAID 
treatment is generally advised. The exception to no. 18 is however strictly limited 
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to patients at high gastro duodenal risk where treatment with lower doses of 
NSAIDs and / or PPI is not sufficient.17 
Annex III suggests that the G-BA is generally critical about combinations if it is a 
fixed dose and no therapeutic benefit is presumed. However, if it can be proven 
that the requirements of § 16 (1) AM-RL 
1. diagnostic or therapeutic benefit  
2. medical need  
3. economic efficiency  
are fulfilled, therapies are cleared for reimbursement by the G-BA and will be 
financed by the GKV. 
For therapeutic concepts, reimbursement should therefore generally be possible. It 
must be proven that the therapeutic concept offers a benefit in therapy and an 
equivalent or better risk profile compared to alternatives. The purpose of 
therapeutic concepts is finding a reasonable combination of products that is 
supported by a strong biological and medical rationale. The interaction of the 
products has been tested in studies and trials so that accurate safety evaluation can 
be done. Due to the flexible dosage regime of the individual parts of the 
therapeutic concept the risk of under- or overdosing is significantly lower than in 
fixed combinations as it is based on the patient’s need,. Another advantage with 
the approval of therapeutic concepts would be that it is more likely that the 
complete concept will be financed and not just parts of it. Even the necessary test, 
which would be part of certain concepts, can be reimbursed, because their 
contribution to the therapy would be sufficiently demonstrated in the authorisation 
procedure. In conclusion, reimbursement does not seem to be a major obstacle in 
the German legislation for the introduction of therapeutic concepts.  
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6.6 Patent protection 
Research, development and clinical testing for drugs are complex and costly in 
terms of time and money. Patent protection is therefore essential for any drug 
development and a strong incentive for industry. Patents prevent that competitors 
benefit from original research and are therefore an important aspect for the 
development of therapeutic concepts. If no patent or similar protections exist, 
there is a risk that companies invest in extensive research for a therapeutic 
concept, which might afterwards be used by competitors and generic producers. 
Patents are incredibly useful and important for the industry, which is illustrated by 
the current trend in the industry. After the expiry of a drug patent, the industry 
often places new similar products on the market (“Me-too” product with the same 
structure-activity relation) that allows new patents and sales.175  
An adequate protection should necessarily be provided as an incentive for 
therapeutic concepts. As therapeutic concepts present new indications and new 
dosage schedules for a defined patient population, “usage” patents might be 
applicable. The CMDh outlines "usage patent" as a claim to a new use for already 
known or patented drugs. Use may relate on new indications, formulations or 
dosage regimens: 
‘Usage’ Patents claim novel ‘uses’ (indications, formulations, routes of 
administration, dosage schedules, patient populations etc.) for known / 
already patented active substances to the extent that the ‘usage’ patent 
satisfies the requirements for a valid patent, it confers an independent full 
period of patent protection in relation to the claimed invention. This can 
give rise to potential patent infringement in the event that a generic of an 
innovator product for which the initial patent protection period has 
expired but which is still protected by a ‘usage’ patent is authorised by a 
competent authority which would normally require the generic 
authorisation to conform to that of the innovator with respect to the 
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summary of product characteristics and package leaflet and labelling as 
appropriate.176  
Other incentives for the protection of therapeutic concepts might include 
extension of the supplementary protection certificate (SPC). SPCs are granted for 
products such as medicinal products that require an approval. The authorisation 
processes may require years in which the patent cannot be used commercially, 
therefore a regulation has been created that allows to extent the market exclusivity 
by SCP. The SPC comes into force after the patents of the product is expired and 
extents the protection of a patented product. The maximum lifetime of an SPC is 
five years. However, there are already initiative in which the SPC can be 
extended. For example, the SPC can be extended for further six months for 
products for which data from an approved Paediatric Investigation Plan (PIP) are 
submitted. Similar approaches might be conceivable for therapeutic concepts with 
a major impact on public health, for example in indication in which only a few 
treatment opportunities exist.  
  
                                                 
176
 CMDh. Questions & Answers Usage Patent. October 2012 [Accessed on: 26 June 2016]. 
http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Questions_Answers/CMDh-
279-2012-Rev0-2012_10.pdf.  
7 Outlook und proposal of changes 
 
118 
7 Outlook und proposal of changes 
The approach of therapeutic concepts applies primarily on indications with a high 
medical need, in which a strong rationale for combination therapy for selected 
patient populations exists. The approach follows the current development of 
increasing use and need for combinations in modern therapy. This drift is 
particularly obvious in the field of personalized medicine and the oncology sector 
where therapy with multiple products is common. Especially in these disciplines, 
the conditions are often life-threatening and difficult to treat. This development is 
currently not appreciated enough in the regulatory landscape. To adjust the 
existing legislation towards new paths therapeutic concepts are proposed to meet 
the demands.  
As a first step, the EMA would have to officially introduce and define the term 
‘therapeutic concept’. Implementation of therapeutic concepts would make use of 
the existing framework and could be achieved by introduction via EMA guideline 
on the regulatory path and requirements. A positive benefit-risk balance must be 
demonstrated and would still be the main criteria in order to obtain the marketing 
authorisation, as in any other authorisation route.  
An outline on a prospective guideline for therapeutic concept development based 
on the implementation requirements discussed in this thesis is summarized in this 
section and issues that need to be clarified are discussed. 
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GUIDELINE ON THE DEVELOPMENT OF THERAPEUTIC CONCEPTS 
INTRODUCTION 
The introduction should outline that combinations in a therapeutic concept shall 
be based on valid therapeutic principles and shall be justified by a biological 
rational. The use of therapeutic concepts has the potential to facilitate the 
availability of approved combinations therapies for a defined patient population 
with a high medical need and a well-understood condition.  
DEFINITION 
The term ‘therapeutic concept’ must be outlined and defined based on the 
definition and explanations given in Chapter 4.1.  
SCOPE 
The guideline describes the relevant requirements that should be considered in the 
development of therapeutic concepts in order to support a safe use of the 
therapeutic concept in humans. The general requirements for the development and 
marketing authorisation also apply for therapeutic concepts, as well as relevant 
standards for components of the therapeutic concepts that are not medicinal 
product, such as diagnostics. The guideline does not apply to fixed combinations 
or combinations packs. 
LEGAL BASIS 
Legal basis for a guideline on therapeutic concepts should be Directive 
2001/83/EC (as amended) as well as medical device directives whenever medical 
devices, especially in-vitro diagnostics, are involved in the therapeutic concept 
and the applicable standards. It must be clarified whether the entire concept can 
and must be approved under Directive 2001/83/EC including any medical devices 
incorporated in the therapeutic concept. This procedure would initiate a paradigm 
shift in the medical device legislation. It would mark the start of the approval of 
high-risk medical devices as is already demanded by many. By approving the in-
vitro diagnostics used in a therapeutic concept the importance of the medical 
device in that particular treatment combination for the therapeutic success is 
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recognized. It must furthermore be determined if additional monitoring under the 
medical device regulation by a notified body will still be applicable. Considering 
the comparatively high risk of therapeutic concepts this may further improve the 
concept’s safety profile.  
It should be outlined under which approval procedure an authorisation can be 
obtained. Based on the complexity of therapeutic concepts due to the interaction 
of the different components of the concept a centralised procedure seems to be 
advisable. For therapeutic concepts with indications defined in Regulation (EC) 
no. 726/2004 the centralised procedure would be mandatory in any case. The 
centralised procedure should also be recommended for therapeutic concept 
combinations in which a close monitoring of the combinations is necessary, for 
example in therapeutic concepts with novel substances or with substances that 
previously shown a high risk. It should be considered if national procedure can be 
allowed under certain circumstances, such as therapeutic concept combinations 
with corresponding tradition in the concerned Member State. However, as 
therapeutic concepts represent an entirely new approval process, which must 
prove itself first, a centralised procedure is deemed the most reasonable approach.  
GENERAL CONSIDERATIONS 
The guideline should refer to the main questions in therapeutic concept 
development and should provide guidance on how to handle these issues.  
These considerations include: 
1. Justification of the therapeutic concept 
The concept must be based on the generally accepted terms for 
combinations. A scientific rationale shall be provided for the use of the 
combination. This may include pharmacological interactions (such as 
additive effects, reduction of adverse effects), genetic backgrounds (e.g. 
presence or absence of a particular gen), or other conclusive reasons that 
justify an improved efficacy profile. The potential interactions of the 
compounds within the therapeutic concept must be considered in non-
clinical and clinical studies.  
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2. Possible therapeutic concept scenarios  
Combination of drugs or combinations of pharmaceutically active 
substances with diagnostics are possible.  
a. Combination of two or more medicinal products 
b. Combination of one or more medicinal product with a 
companion diagnostic  
The compounds are not part of a fixed combination or a combination pack 
(other guidelines apply for these combinations) but may be dispensed 
separately. 
The components of the therapeutic concepts can either be already 
approved components, a combination of new components or new actives 
substances or contain both, approved and new components. 
  
3. Indication and patient profile 
The criteria for patient population and possible patient stratification for a 
specific therapeutic concept shall be clearly outlined and described. 
Wherever possible, a scientific rationale shall be presented to explain why 
the therapeutic concept is particularly eligible for the patient population 
(e.g. genomic parameters). Risk consideration regarding patient 
stratification should be evaluated.  
 
4. Pre-clinical development and design of clinical studies 
Pre-clinical development and clinical trials with therapeutic concepts 
require extensive planning to prove the effectiveness and safety of the 
combination. Depending on the components of the therapeutic concepts 
(new or already approved components), non-clinical testing and clinical 
trials shall be planned according to the expected risk of the combination 
and the evidence already available for the combination and the individual 
components. Wherever feasible a two-armed study approach (combination 
vs. SOC or placebo) shall be accepted when the study design is selected to 
satisfactory demonstrate safety and effectiveness of the combination in 
order to not unnecessarily expose patients who are not likely to benefit 
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from the therapy. For new components, additional studies to evaluate 
toxicity, safety or effectiveness may be applicable in order to ensure a safe 
use.  
 
5. Co-development 
Co-development of the concept should be given thorough consideration. In 
terms of safety and effectiveness, an early beginning of the co-
development is desirable to investigate the possible interactions. Special 
focus should be given to the development of diagnostics that are required 
for a safe and effective use of a medicinal product to establish the 
appropriate clinical validity of the diagnostic.  
 
6. Labelling requirements  
The labelling shall identify the distinctive requirements of the therapeutic 
concepts. It shall include explanations regarding the importance of the 
combination therapy, the selection of patients and the other components of 
the therapeutic concept. Three different scenarios are possible which shall 
be reflected within the labelling to allow patients and physicians to 
identify the status of the product. 
a. The drugs or drug/diagnostic combination are only to be used within 
the approved therapeutic concept, the mandatory combination should 
be clearly pointed out. 
b. One or more compounds of the therapeutic concept are also used 
individually for an approved purpose but sold under the same brand 
name 
c. One or more compounds of the therapeutic concept are also used 
individually for an approved purpose but sold under different brand 
names for individual use and use in the therapeutic concept. 
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8 Discussion 
While combination therapies have been and will always be part of medicine they 
are however not always advantageous. To avoid the use of futile or even 
dangerous combinations several regulations were introduced over time. For the 
development and authorisation of fixed combinations, for example, a biological 
rationale must be present to justify the intended joint use.  
However, the area of combination therapies is still lacking satisfying regulations 
and new options for the authorisation of combinations should be established. One 
possibility is the introduction of so-called therapeutic concepts, which are 
introduced by this thesis. In a therapeutic concept, several pharmaceutical 
products (and eventually diagnostics) shall be authorised in a free combination as 
a joint concept. In this way, a flexible therapeutic approach is approved that has 
undergone joint development and which can be used in accordance with the 
patient characteristics. This type of authorisation is a useful complement to the 
recent approval route that is mainly focused on single drug approval. New 
findings in science, however, offer many new insights that and why combinations 
in certain patient groups are particularly favourable and should therefore be used. 
Combinations have always been applied if they have proven to be useful for a 
particular disease or group of patients. Examples for combinations that are used 
since many years that are based on subgroups stratification and disease causes are 
the treatment of tuberculosis or helicobacter, which are discussed in this thesis. In 
these cases, there is a very strong biological rationale why these populations in 
particular are successfully treated with combinations. It is very likely that new 
knowledge about cellular pathways and disease origins lead to the conclusion that 
combinations are useful in many more cases and are thus applied more often. This 
knowledge is mainly based in the research performed in personalized medicine, 
which aims to investigate the genetic influence on diseases and cellular pathways.  
Personalized medicine is presented as one of the main application areas for 
therapeutic concepts as several aspects that are important for therapeutic concepts 
are included such as patient stratification based on a scientific rationale. In 
addition, a high medical need is identified in this field and combinations are often 
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applied in the treatment. In many cases, a diagnostic is necessary for a safe and 
effective therapy as well. It was found that therapeutic concepts could be used as a 
new approach for several regulatory challenges that personalized medicine 
displays today. For example, biomarkers and companion diagnostics would be 
involved in the therapy from the outset. Providing the new possibility of 
therapeutic concepts combined with further research in personalized medicine and 
patients’ stratification could possibly create new indications that would fall under 
the scope of the orphan drug regulation leading to more orphan drug applications. 
However, this is not considered a threat to the current intentions of the orphan 
drug regulation as patient safety and efficacy of a therapy should be prioritized.  
Today medical guidelines are commonly used as a guide on how to apply 
combinations. Medical guidelines are however only recommendations and lack a 
legal basis and they are not comparable to an authorisation process. The uncertain 
legal status of medical guideline is thoroughly discussed. It was found that 
approval of therapeutic concepts would improve the uncertainties that are 
associated with medical guidelines. Medical guidelines are often the result of long 
years of experience with certain product combinations. Therapeutic concepts 
could accelerate the establishment of certain combinations in the standard of care 
compared to medical guidelines due to prospective planning of trials and scientific 
evaluations. As a result, approved therapeutic concepts are a compulsory therapy 
that offers more security for patients and physicians in regards of safety, efficacy 
and liability. Flexibility in treatment is an important aspect to respond to patient 
characteristics. Additionally approval of therapeutic concepts would provide the 
possibility of reimbursement of an entire concept not only parts of a necessary 
treatment.  
A central step in therapeutic concept is the selection of an eligible patient 
collective. Because certain tests are needed for genome based patient 
stratification, the combination of medicines and diagnostic is becoming 
increasingly important. Therefore, diagnostics shall definitely be included in a 
therapeutic concept where needed in order to have a valid diagnostic tool that has 
been tested in the clinical development.  
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Many aspects and approaches for a therapeutic concept introduction already exist. 
FDA for example encourages co-development of products for use in combinations 
and gives guidance on design of clinical trials. For therapeutic concepts, the FDA 
approach should be extended to include not only unmarkted products but also 
already approved products in a combination use as well as diagnostics that are 
essential for the combination therapy. Introduction of the adaptive pathway by 
EMA shows that the European legislation has recognized that the current system 
is not suitable for all regulatory issues and that new innovative and more flexible 
ways of approval are being sought to satisfy different needs. Therapeutic concepts 
are a reasonable way to merge different approaches together and transform them 
into regulatory standards.  
In order to establish therapeutic concepts as an attractive future way of 
authorisation sufficient incentives should be provided for industry and authorities. 
The benefits of the new regulation must be stated clearly and the pathway to the 
authorisation must be well defined for therapeutic concepts to be accepted by all 
stakeholders. Pharmaceutical companies need to be aware that therapeutic 
concepts approval exists in order to adapt to the new regulation and the role of the 
competent authorities and agencies such as the EMA should be well understood. 
A guideline issued by the EMA would provide the necessary guidance to fulfil the 
necessary requirements concerning sufficient safety and efficacy of the 
combinations. The strong focus on co-development of therapies should be 
emphasized. Considerations whether the EMA should provide special support for 
particular combinations with a major public interest should be made additionally. 
It should also be considered if therapeutic concepts approval will only be possible 
using the centralised approval procedure or if decentralised or mutual recognition 
procedures may also be used. Since therapeutic concepts are intended to 
strengthen the control of certain combinations and novel combinations introduced 
to the market, the centralised procedure seems to make the most sense. However, 
national approval could prove useful for the authorisation of old products in a new 
therapeutic concept, particularly if this combination already has a corresponding 
tradition in the concerned country.  
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Therapeutic concepts provide benefits in different areas, including better control 
of combination for both health care professionals and authorities. The 
combinations will be better studied, thus providing more information about 
possible interactions and risks, which leads to a safer use of certain combination 
regimens. Therapeutic concepts close the gap between treatment reality and 
medical practice. As discussed in this thesis, special considerations must be made 
concerning clinical trials, labelling, and implementation of medical 
devices/diagnostics into the therapeutic concept as well as vigilance strategies to 
address the extraordinary status of a new authorisation route.  
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Summary 
In this thesis, the limitations and opportunities of the current regulation 
concerning therapy with product combinations are outlined.  
It was found, that combinations are and always have been a frequently used 
approach in the day-to-day medical practice and the explanation why 
combinations are often a reasonable approach for the treatments of certain 
conditions are numerous. Despite several implemented procedures for the 
approval of combinations (fixed combinations, combination packs) not all 
scenarios for combination use are covered by the regulations. Amongst other 
things, this includes combinations administered individually in different doses, or 
combinations with medical devices that are indispensable for the safe and 
effective use of a treatment regimen. 
Particularly personalized medicine exemplifies the many factors that influence 
modern therapy and justify the use of combinations by a scientific rationale 
supported by the identification of patient characteristics such as certain 
biomarkers. Stratification of patients allows a more effective and safer therapy. 
Despite gaining more importance this field of modern combination therapy is 
reflected poorly in the regulations and has been found to be in need of 
improvement. The increasing complexity of medical knowledge requires a more 
flexible approval system to adapt to the rising and ever changing needs. 
In this thesis, the introduction of a new marketing authorisation route based on the 
current legal framework is proposed and the requirements for the presented 
approach are discussed. Introduction of so-called “therapeutic concepts” provides 
a new way of approving combination therapies. In a therapeutic concept several 
products that belong to the same treatment regimen for a defined patient collective 
are authorised for combination use in which the single compounds or products are 
administered separately on an individual basis and dosage; they are not 
necessarily part of a combination pack. Therapeutic concepts may combine 
several pharmaceutical compounds or a combination of pharmaceutical and 
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medical device should such be necessary for a safe administration, e.g. when the 
medical device is a diagnostic for a genetic makeup. 
The expansion of the existing regulatory system by the approach proposed in this 
thesis not only reduces uncertainties in regards to combination therapies, but also 
brings a significant increase in patient safety. 
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